December 2016

20

Paroxysmal Nocturnal Hemoglobinuria Treatment Receives Fast Track Designation

RDR Staff; Published Online: Tuesday, Dec 20, 2016

Apellis Pharmaceuticals announced that their orphan drug APL-2, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) received Fast Track Designation by the FDA.

APL-2 is designed for patients who experience hemolysis and require RBC transfusions even while taking eculizumab.

APL-2 currently in two Phase Ib clinical trials. One trial assessing doses APL-2 administered by daily subcutaneous injection (SC) in patients with PNH who have not received the standard of care in the past, and the other is assessing doses of APL-2 as an add on with standard care.

Results

APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained through the dosing period.

About APL-2

APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b, effectively blocking all three pathways of complement activation (classical, lectin, and alternative) with a particularly high potency against the alternative pathway. 

About PNH

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder in which red blood cells break apart prematurely. It is an acquired hematopoietic stem cell disorder.

Some hematopoietic stem cells in individuals with PNH are defective and consequently produce defective blood cells. These defective red blood cells of PNH are extremely susceptible to premature destruction by a particular part of a person’s own immune system called the complement system.

 About Fast Track Designation 

The FDA’s Fast Track program is designed to facilitate and expedite development and review of new drugs. Through the Fast Track program, a product may be eligible for priority review at the time of BLA and may be eligible to submit sections of the BLA on a rolling basis as data become available.

APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained through the dosing period.

13

Green Biologics Begins Customer Shipments at First Commercial Plant

Little Falls, MN, facility produces 100 percent bio-based n-butanol and acetone

Ashland, Virginia USA and Abingdon, Oxfordshire U.K. (December 13, 2016) – Green Biologics, Ltd., a UK industrial biotechnology and renewable specialty chemicals company, announced today the start of commercial shipments of bio-based n-butanol and acetone from its manufacturing facility in Little Falls, Minnesota.

Over the past year, Green Biologics has built a robust pipeline of domestic and export customers combined with multiple partnerships to bring its products to downstream markets. These include distribution agreements with Acme Hardesty, Nexeo Solutions, and Caldic as well as a strategic partnership with HOC Industries, a custom blender, packager and distributor of consumer and government products. The company is collaborating with other industry leaders in a range of specialty markets and applications where performance and sustainability drive value.

“The start of our first commercial facility is a critical milestone in building our position within the industry as a global renewable speciality chemicals company,” said Sean Sutcliffe,Chief Executive of Green Biologics. “We’re very proud to announce the start of shipments to key customers in highvalue markets and look forward to working with existing and new collaborators to bring a wide range of sustainable, environmentally-friendly products to shelves.”

Offered as a high-performance, high purity, fully-sustainable alternative to conventional petrochemical-based commodities, Green Biologics’ speciality chemicalsaim to drive value in customer applications and downstream markets ranging from specialty coatings, pharmaceuticals, cosmetics, personal care and consumer products. Both butanol and acetone products carry the brand name BioPure™ and have receivedUSDA BioPreferred® status. As a member of the American Chemistry Council (ACC), Green Biologics’ commercial facility is actively working towards meeting Responsible Care® standards.

7

Cognito Therapeutics Launched with Exclusive License to Promising Alzheimer’s Research from The Massachusetts Institute of Technology

Boston, Mass. and San Francisco, Calif. — December 7, 2016 – Cognito Therapeutics announced today that the company has secured an exclusive worldwide license to the intellectual property developed from scientific discoveries by Li-Huei Tsai, Ph.D., and Ed Boyden, Ph.D., professors in the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology (MIT). The company was launched earlier this year with Series A financing from Morningside Venture.

The scientific discoveries are featured in the December 8th issue of Nature. Working with mouse models of Alzheimer’s disease, the team of scientists showed that by using a unique and totally non-invasive method of stimulation, they were able to restore gamma oscillation in the brains of the mice, which in turn activated the microglia cells to remove beta amyloid plaques in the brains. These plaques are characteristic of the brains of Alzheimer’s disease patients, which are also deficient in gamma oscillation.

“These results have opened up new doors to our understanding of Alzheimer’s,” said Prof. Tsai, Picower Professor of Neuroscience at MIT and co-founder of Cognito Therapeutics. “By demonstrating the underlying importance of these brain wave signatures, we have potentially uncovered a key to solving this disease in humans.”

Tsai and Boyden co-founded Cognito Therapeutics to translate their findings into a treatment for Alzheimer’s patients. The company has filed an extensive portfolio of patents covering the applications of this novel approach to treating a variety of neurological disorders.

“This is truly breakthrough science,” said Gerald Chan, ScD, founder of Morningside and board member of Cognito Therapeutics. “It has the potential of being a game changer in our struggle to find an effective treatment for Alzheimer’s disease. The social impact of such a treatment, if successful, would be enormous, as dementia is becoming the leading medical problem of an aging population.”

Cognito Therapeutics is based in Cambridge, Massachusetts, and at the San Francisco incubator TheraNova, a medical device developer with expertise in accelerating time-to-market for innovative medical technologies.

“A device-based approach to Alzheimer’s is novel,” said Daniel Burnett, M.D., chief technology officer of Cognito Therapeutics and founder of TheraNova. “We are excited to be working with Morningside, which has shown an unwavering commitment to bringing this technology all the way into the clinic.”

5

ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS

• MIMESIS will accelerate and enable large scale development of ENYO Pharma’s novel discovery approach aimed at identifying new preclinical assets against infectious diseases and cancer from innovative drug discovery starting points inspired by viruses.

Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).

The SME Instrument is part of Horizon 2020, the EU framework programme dedicated to innovation and research managed by the European Commission. It belongs to the pillar “Industrial Leadership” of H2020 and aims to support high growth and highly innovative SMEs with global ambitions.

ENYO Pharma’s MIMESIS project applied for the June 2016 cut-off under the topic “Dedicated support to biotechnology SMEs closing the gap from lab to market”. MIMESIS has been selected by an independent jury of four experts recognised for their scientific and business expertise. The company will receive 2.5 M€ corresponding to the financing of 70% of the total project budget (€3.6 million).

After a feasibility Phase that generated ENYO’s internal drug development programme on an autophagy target, MIMESIS will be expanded to an industrialised scale to accelerate the discovery of new therapeutic targets and innovative new chemical entities against infectious diseases and cancer.

Dr Eric Meldrum, ENYO Pharma’s Chief Scientific Officer commented, “We are very honoured to receive the recognition from the Horizon 2020 jury in what was a highly competitive process. MIMESIS represents a real paradigm shift in the development of new innovative drugs for pathologies where the medical need is immense. This financing will enable us to screen our library of original peptides and small molecules on hundreds of intracellular human targets previously untapped by the pharmaceutical industry.”

For this project ENYO Pharma has designed a proprietary library of 10’000 small molecules to modulate host cell biology and also capable of disrupting protein:protein interactions (PPIs) between pathogens and the host. This library of developable chemical templates will be screened in phenotypic assays for inhibitors of the replication cycle of several viruses (Influenza, RSV, HRV, Zika) and a mycobacterium (TB). As this library is designed to modulate host cell biology, it will also be screened for inducers of Immunogenic Cell Death (ICD) in tumors. With €3.6 million over 24 months, most promising chemistries will be the starting point for numerous hit to lead optimisation programmes funded within the EU grant. Those optimisation efforts focused on novel intracellular targets will generate valuable Intellectual Property. Upon completion of MIMESIS, ENYO Pharma will further optimise its best chemical series either internally or in collaboration with other pharmaceutical companies up to clinical proof of concept.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 739086- MIMESIS

2

Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH

C3 inhibitor reduces hemolysis in patients with PNH, is generally well tolerated

LOUISVILLE, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase Ib open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired, potentially lifethreatening disease characterized by complement-mediated hemolytic anemia.

Interim results suggest that APL-2 reduces hemolysis in patients with PNH who receive daily subcutaneous injections of APL-2 as monotherapy or as an add-on to the standard of care, eculizumab. With APL-2 (270 mg) as monotherapy, three out of three (3/3) PNH patients achieved a reduction in lactate dehydrogenase (LDH) levels to below the standard for control in PNH (500 U/L). With APL-2 (270 mg) as add-on to eculizumab, six out of six (6/6) previously transfusion-dependent PNH patients did not require transfusions during the study and five out of six (5/6) PNH patients achieved hemoglobin levels within the normal range for healthy individuals.

All 15 PNH patients who have been dosed across the two trials to date have completed at least one month of dosing, with five having received more than three months of dosing. Based on preliminary assessment, APL-2 is generally well tolerated.

“Establishing that systemic inhibition of C3 is feasible with daily subcutaneous injections of APL-2 in patients with PNH is a significant achievement that validates C3 as a target in the complement pathway,” said Cedric Francois, M.D., Ph.D., chief executive officer of Apellis. “APL-2’s unique ability to target C3 and block all three pathways of the complement system is indicative of its potential to be an effective treatment for multiple complement-driven diseases. We are encouraged by the preliminary results APL-2 has demonstrated, as well as the favorable safety data observed thus far in the Phase Ib trials and our previous studies in healthy volunteers. All patients in the Phase Ib trials will have completed three months of dosing in January 2017.”

Apellis will present the Phase Ib interim results today at the International PNH Interest Group (IPIG) Annual Scientific Assembly and will present the poster “APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers” tomorrow at the American Society of Hematology (ASH) Annual Meeting.

Why High School Students Should Seek Out Peer Mentors for College Applications

Find out how CollegeVine’s near peer mentors can help high school students successfully apply for college.

DEC 2, 2016 2:59PM EST — When Ling Ritter applied early decision one of her top college choices, she had doubts about her ability to get in, but her guidance counselor told her she had a strong enough profile that the school would either accept or defer her, but not deny. So, when she received a rejection from that school, she was flummoxed. Ling, now 19, went back to that counselor who, this time, told her the rejection was an “indicator of [her] competitiveness,” and that she should remove any other “reach” schools she was planning to apply to. She didn’t listen. Instead, she added a few “safe” schools, and applied to her “reach” options as well — and was accepted to 13 out of 17, including Princeton University, where she’s currently a sophomore politics major.

Ling’s college application process was rocky, perhaps in part because her main source of guidance was an adult counselor who was also responsible for helping out all of her classmates. After all, according to CollegeVine, the average public school student receives only 38 minutes with her school’s guidance department over the course of four years. But, Ling is determined to make it better for other high schoolers. She now works as a “Near-Peer Mentor” with CollegeVine, which pairs high schoolers with college students who not only still have the application process fresh in their minds, but also can lend insight on actual, current college life. As part of her one-on-one relationships with her mentees, Ling (who went through training with CollegeVine for the job) helps with their school selections, applications, and essays, managing deadlines and timelines, and more.

And she’s not alone. CollegeVine’s college mentors attend schools around the country, and represent more than 20 different majors, extracurriculars, and individual experiences. We caught up with Ling to find out even more about the program — and why it’s awesome for both the mentors and the mentees.

Teen Vogue: How do you think having a near-peer mentor would have changed your college application experience?

Ling Ritter: Near-peer mentors help make college applications less of a guessing game. There is no silver bullet, no magic formula. However, after joining the CollegeVine team and going through their consultant training program, I now understand that there are ways mentors can help students authentically maximize their strengths in order to stand out in the applicant pool.

TV: What do you wish a college student would have or could have told you during that process?

LR: One piece of advice high school seniors frequently hear during the application process is, “Just be yourself.” I want to double down on that. You don’t need to be anyone else to succeed — you need to know that you are enough. But I also want to expand on this idea: Be yourself and understand who you are. Colleges are looking for individuals who demonstrate that they have been thinking about the intersections of their different identities, extracurricular interests, and academic pursuits, and that they are exploring how they can apply their unique perspectives to the world around them. An application is a very condensed representation of you, so seek out ways to add complexity and color.

TV: As a mentor, what kind of advice do you give? What aspects of your college experience do you share?

LR: Although [we follow a] curriculum, I will share anything about my college experience that my student wishes to know. CollegeVine’s pairing process is very specific, so I have thus far always been paired with a student who either is really interested in Princeton or has many shared passions in common with me (or both). This often leads to all sorts of great conversations [and questions, like], “Should I submit an arts supplement?” [or] “How do I begin to navigate the myriad career paths that stem from my interests?”

TV: Do you have any moments from your mentoring experiences with high school students that especially stand out to you?

LR: My favorite thing to hear from a student is, “Oh! I didn’t think I could do that.” Many students come in believing that college applications have to be weighty, and serious, and formal. While it’s important to demonstrate diligence, it’s equally important to convey personality. The times in which I was able to help students discover new and creative ways of expressing themselves, or showcasing quirky hobb[ies] that [don’t] fit within the confines of a traditional resume are definitely special moments for me.

TV: What’s the best part about being a near-peer mentor?

LR: Getting to know my students has been incredible. They are all such kind hearted, multifaceted, and spirited individuals. I am rooting for them in their college searches, and I know that, when spring comes around, the tables will turn, and they will be the ones choosing college[s] that fill them with pride and excitement for the future.

TV: How does mentoring high school students affect your current college life and path?

LR: Mentoring gives my college life a sense of purpose. Being raised by immigrant grandparents instilled in me the importance of not only being thankful for the resources available to me, but also using those resources to help future generations obtain the same opportunities. CollegeVine gives me a platform to do so on a very personal level.

TV: What about your confidence and outlook as a student and a person?

LR: Working with CollegeVine has given me insight into some of the potential reasons…behind my own admittance to Princeton. This, coupled with hard work paying off in the classroom, has really helped me prove to myself that I belong here.

TV: If you could give one piece of advice to students beginning the college application process, what would it be?

LR: The weight of a hundred rejections is still less than that of refusing to try and always wondering if things could be different. Rub some dirt on it and get back to being awesome.

November 2016

30

MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4

HAYWARD, Calif. and SHANGHAI, China – November 30, 2016 – MicuRx Pharmaceuticals, Inc. today announced the start of a Phase 1 clinical trial of a new antimicrobial agent, MRX-4, for the treatment of infections caused by Gram-positive bacteria including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE). MRX-4 is a prodrug form of the oral antibiotic MRX-1, presently in Phase 3 clinical trials in China for the treatment of complicated skin infections.

This comprehensive Phase 1 trial, now enrolling patients at a single center in the United States, will evaluate safety, tolerability, pharmacokinetics and bioavailability of the oral formulation of MRX-4. The study will enroll 122 healthy subjects in nine single- and four multiple-ascending dose cohorts. Concurrently, the safety, tolerability, and pharmacokinetics of the intravenous formulation of MRX-4 will be evaluated in 60 healthy subjects of five single- and four multiple-ascending dose cohorts, along with an oral to IV crossover study.

“We anticipate that success in this Phase 1 trial would enable a rapid transition into advanced clinical studies in the U.S. for this new means of efficient delivery of our antibiotic systemically,” stated Zhengyu Yuan, Ph.D., president and CEO of MicuRx.

MRX-1 is a next-generation oxazolidinone agent that has shown notably improved hematopoietic safety compared to first-generation antibiotics, such as linezolid, while maintaining excellent efficacy characteristics for this class. The prodrug form of MRX-1, named MRX-4, serves to expand its utility into both intravenous and enhanced oral applications.

29

Green Biologics Receives USDA Certification

Renewable Specialty Chemicals Company Receives Certification Under USDA BioPreferred® Program

Ashland, Virginia and Abingdon, Oxfordshire U.K. (November 29, 2016) – Green Biologics, Inc., the U.S. subsidiary of Green Biologics Ltd., a U.K. industrial biotechnology and renewable chemicals company, announced today that its high purity bio-based n-butanol and acetone have received official certification under the USDA BioPreferred® program. The products are now certified as 100 percent bio-based and are marketed under the BioPure™ brand.

“Having our n-butanol and acetone named as USDA Certified BioBased Products is yet another milestone that we can point to when demonstrating the value and differentiation of our products from conventional petrochemical-based commodities,” said David Anderson, Global Vice President of Marketing for Green Biologics.

18

Stealth BioTherapeutics Announces Positive Phase 2 Clinical Trial Findings for Patients Undergoing Renal Angioplasty

Data support company’s cardiorenal program, including three ongoing heart failure trials

Single elamipretide infusion improves kidney microvasculature and function after renal artery angioplasty

BOSTON – November 18, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today presented results from the EVOLVE trial, which demonstrated that a single dose of elamipretide prior to renal artery angioplasty and stenting procedures improved kidney function and blood flow for three months post-procedure. The data were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2016 in Chicago.

“Patients undergoing renal angioplasty and stenting, intended to open up kidney arteries blocked by atherosclerosis, often fail to regain normal kidney function due to tissue damage during the procedure, possibly due to the sudden replenishment of oxygen to starved tissues,” said Dr. Stephen Textor, the principal investigator for the trial. “The study results validate our preclinical findings and our underlying hypothesis that elamipretide may help prevent acute kidney injury by preserving mitochondrial function in cells and ultimately improve measures of kidney function in these patients.”

15

SKSpruce Technologies Finalist WBA Awards

San Jose, CA, November 15, 2016—SKSpruce Technologies, an emerging Silicon Valley leader in carrier-class Wi-Fi, is a finalist for the Wireless Broadband Alliance (WBA) “Best Next Gen Wi-Fi Network Infrastructure” award, recognizing and celebrating excellence in
wireless innovation.

The WBA recently announced the shortlist for its annual WBA Industry Awards 2016, taking place at the Wireless Global Congress, November 16-17 in San Jose, California. The finalist entry recognizes SKSpruce’s Wi-Fi solution used in the largest integrated Wi-Fi/cellular system in the world, deployed in Japan by SoftBank, a leading global carrier with more than 100 million subscribers. The SoftBank Mobile Wi-Fi system has 460,000 access points throughout the country seamlessly integrated into their 4G LTE network providing transparent uninterrupted handover between 4G LTE and Wi-Fi, delivering a superior user experience. SoftBank Mobile’s entire Wi-Fi network is controlled by the SKSpruce SKG10000 gateway, and its integration to the core mobile network is provided by SKSpruce.

14

Stealth BioTherapeutics Initiates Phase 1 Study of Elamipretide in Dry Age-Related Macular Degeneration

Top-line data from study evaluating elamipretide in patients with dry age-related macular degeneration expected mid-year 2017

BOSTON – November 14, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of ReCLAIM, a Phase 1 study evaluating elamipretide in intermediate age-related macular degeneration (AMD). Top-line data are expected mid-year 2017.

“There are currently no FDA-approved treatment options for dry AMD, so we are eager to better understand the effect that elamipretide may have in treating these roughly 13 million patients,” said Dr. Scott Cousins, the trial investigator, and Professor of Ophthalmology and Director of the Duke University Center for Macular Diseases. “Mitochondrial dysfunction that stems from various environmental toxins may be an important causative factor in dry AMD, and in laboratory models, elamipretide appears to prevent mitochondrial dysfunction in the retinal pigment epithelium.”

ReCLAIM is an open-label study to evaluate the safety and tolerability of 12 weeks’ treatment with daily subcutaneous injections of elamipretide in patients, age 55 and above who have at least one eye with intermediate AMD, and have either: a) high-risk protein deposits (drusen) on the retina without any geographic atrophy (GA), a characteristic of advanced AMD which can result in the loss of photoreceptor cells or b) GA with an unaffected central fovea (noncentral GA). The study’s primary endpoints are safety and tolerability, and the secondary endpoints are changes from baseline in physical/ophthalmic examinations and feasibility of subcutaneous injections in this patient population.

“ReCLAIM will build upon our ongoing ophthalmic program to help us better understand the potential of elamipretide to treat back of the eye diseases as well as the effects of the treatment to slow the aging process in eye tissue,” said Stealth Chief Executive Officer Reenie McCarthy. “We look forward to evaluating initial results of this study mid-year 2017.”

8

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

Houston, TX – November 8, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of Florida, Gainesville to develop a novel oncolytic virus platform.  The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers.

A major advantage of the myxoma virus is its ability to attach to T lymphocytes and other white blood cells, which are then delivered to the patient to trigger tumor cell killing and antitumor immunity.  Myxoma virus can be armed with multiple immune stimulatory genes, a feature shared by other large DNA virus such as herpes simplex and adenovirus.

“The myxoma virus has unique properties for attacking cancer,” said CEO Frank Tufaro, Ph.D. “We think this technology platform provides a new modality for delivery of a potent oncolytic virus to tumors by co-administering it along with T cells.  We look forward to testing this “Trojan horse” strategy in the clinic.”

“The myxoma virus is a novel oncolytic candidate that does not infect normal human cells but has a unique ability to identify the damaged signaling pathways found in the majority of human cancers; thus, resulting in productive infections in the patient’s cancer cells,” stated Grant McFadden, Ph.D., Professor in the Department of Molecular Genetics & Microbiology at the University of Florida, College of Medicine.

7

Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

Late-breaking poster presents data from elamipretide clinical trial in chronic kidney disease patients at risk of acute kidney injury

BOSTON – November 7, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that the abstract, “Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis” has been accepted as a late-breaking clinical trial poster at the American Society of Nephrology (ASN) Kidney Week 2016 taking place in Chicago, November 15-20, 2016.

“The EVOLVE trial underscores our commitment to our cardiorenal program,” said Stealth’s Chief Executive Officer Reenie McCarthy. “We are pleased to present the details of these results both in the context of our three ongoing Phase 2 heart failure studies, as well as to inform our approach to other diseases of aging in which mitochondrial dysfunction is a contributing factor.”

EVOLVE was a double-blind, placebo-controlled study that evaluated 14 patients ages 40 to 80 with chronic kidney disease (CKD) at risk of acute kidney injury (AKI). The primary endpoint was change in kidney function, and the secondary endpoint was a change in renal blood flow and cortical perfusion.

2

CollegeVine Secures $3.1 Million In Series A Funding

CAMBRIDGE, Mass., Nov. 2, 2016 /PRNewswire/ – CollegeVine, the fast-growing EdTech startup specializing in high school mentoring for college applications, has closed a $3.1 million Series A funding round led by Morningside Technology Ventures (“Morningside”) with participation by New York-based University Ventures.

Morningside is a private equity and venture capital firm. Gerald Chan, its co-founder, has joined CollegeVine’s Board of Directors. University Ventures is a specialty venture capital fund that exclusively focuses on promising ideas in the higher education space.

The announcement was made today by Jon Carson, the CEO of CollegeVine.

CollegeVine was started by two Harvard University students and one University of Chicago student working out of the Harvard iLab. The company uses a near peer model of matching talented college students with high schoolers to help them with the college application process. CollegeVine’s services quickly earned a reputation for its outstanding college admissions results. Two years ago, the company employed 20 college students as consultants; today it employs almost 300.

“There is a huge unmet need for high school students to get proper guidance and mentoring in their planning for college and their application for admission. The fast growth of CollegeVine’s business validates that its services are exactly what high school students are looking for. Optimizing the college application process is beneficial both to the applicants and to the universities,” said Chan.

“With the backing of Morningside and support from University Ventures, we are now positioned to grow the company to meet consumer demand. We plan to use the Series A investment to build out our technology platform and product suite, grow the team, and accelerate our growth,” said Carson. “We are pleased to have Gerald join our Board as he has been a valued partner and mentor over several ventures. I am honored, to be working with him on another new and exciting EdTech venture.”

Morningside was the primary backer of FamilyEducation Network where Carson was both the founder and CEO. FamilyEducation Network became the largest K-12 online network when it was acquired by Pearson Plc for $175 million in 2000.

CollegeVine has recently strengthened its management team with the addition of former Zipcar executive Doug Williams as chief technical advisor and Harvard Business School professor Deepak Malhotra as a member of the board of directors.

1

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

Houston, TX – November 1, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent glioblastoma.

The CAPTIVE trial is evaluating the potential effect of DNX-2401 and KEYTRUDA in patients with recurrent glioblastoma, a disease for which there is neither a cure nor adequate treatment. Leading medical centers in the United States and Canada are participating.

DNX-2401 is a potent conditionally replicative oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response.

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.  This activity enhances the T cell response and leads to effective tumor destruction. KEYTRUDA is currently approved in the United States for advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and advanced head and neck squamous cell cancer (HNSCC).

“Glioblastoma is a difficult disease to treat with conventional therapies,” said Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix. “Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease.”

October 2016

31

Myanmar HTI Project Formally Launched

October, 2016 – SKSpruce Technologies formally launched the Myanmar Carrier-grade Wi-Fi project. A dedicated project team led by Henry Wu (VP of Product, SE & Product Marketing) was set up to ensure the smooth implementation of this project. The project marks the inaugural collaboration between SKSpruce and Myanmar HTI. Aimed at providing excellent data communication services and comprehensively improving user experience, the project will deploy the world-class carrier-grade Wi-Fi solution of SKSpruce in major areas of Yangon. During this project, over ten thousand APs will be deployed in 22 towns (10 towns in phase I) of Yangon to provide Wi-Fi services to 6 million Yangon citizens, in order to improve the data communication capacity of Yangon public areas, and to bring great economic profits and social benefits to Myanmar.

Myanmar HTI project is SKSpruce’s largest project in Southeast Asia this year. Meanwhile, it indicates that SKSpruce is making a significant move to expand Southeast Asian market. SKSpruce is attracting an increasing number of international clients with its continuous product innovation, solution optimization, and technology development.

25

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Patients Hospitalized with Congestive Heart Failure

Top-line results anticipated in second half of 2017

BOSTON – October 25, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction associated with common diseases of aging and genetic mitochondrial diseases, today announced the initiation of IDDEA-HF, a Phase 2 study evaluating elamipretide in patients hospitalized due to congestive heart failure. Heart failure causes more than two million hospitalizations in the U.S. and Europe each year.

“In heart failure, mitochondrial dysfunction may not only be a causative factor, but may also contribute to the progression of the disease and the associated fluid build-up that causes congestion, due to muscle weakness from a lack of energy production,” said Stealth Vice President of Clinical Development Jim Carr. “In line with our findings in elderly patients enrolled in the   trial, we hope to demonstrate the ability of elamipretide to increase energy production to help the heart muscle work better, subsequently relieving congestion in the body.”

IDDEA-HF is a randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of daily treatment with elamipretide in patients who have been hospitalized with congestive heart failure. Up to 300 patients will be randomized within 72 hours of presentation to receive 20 mg daily elamipretide or placebo intravenously for up to seven days. The primary endpoint is change in NT-proBNP, a cardiac biomarker reflecting the level of congestion. Secondary endpoints include change in clinical status and safety and tolerability.

“IDDEA-HF is a key step in our development of therapies for common diseases of aging. These patients have failed current therapies, experiencing an episode of acute decompensation, which highlights the intense need for new options within the heart failure treatment paradigm where we believe elamipretide can have a significant impact,” said Stealth Chief Executive Officer, Reenie McCarthy. “The data from this study, together with our other ongoing trials in heart failure, will help inform our projected Phase 3 heart failure program as well as our approach to other common diseases of aging for which elamipretide may have therapeutic potential.”

17

ENVISIA THERAPEUTICS RELEASES ENV515 (travoprost XR) PHASE 2 DATA SHOWING NINE-MONTH DURATION OF ACTION AFTER A SINGLE DOSE IN PATIENTS WITH GLAUCOMA

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

RESEARCH TRIANGLE PARK, NC – OCTOBER 17, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops.

“ENV515 continues to show great potential with a favorable safety profile and a sustained, clinically meaningful reduction in IOP over the initial nine months,” said Benjamin Yerxa, President of Envisia. “We plan to initiate enrollment in a new cohort of this phase 2 trial by year-end, which will enable us to evaluate the high dosage form of ENV515 that has been formulated with the goal of achieving efficacy comparable to TRAVATAN Z® with a duration greater than 9 months.”

12

New app helps workers track child development, identify autism early

By Amanda Eisenberg, Published October 12 2016, 1:41am EDT –

As employers struggle with retention rates across the board, healthcare technology company Cognoa is trying to keep a specific population employed: parents of children with developmental disorders.

The Palo Alto-based company recently launched Cognoa for Employers, a mobile app that screens children as young as 18 months for developmental disorders, to assist with early detection and cut down on future healthcare costs and missed workdays. The app would be included in a benefits package for parents to assess how their young children are reaching developmental benchmarks and screens for autism, speech delays and ADHD.

With one in six children in the United States diagnosed with a developmental disorder, according to the Centers for Disease Control and Prevention, the impact affects parents who work full-time.

“There is a greater pressure on one of the parents to leave the workforce and stay home with the child,” says Cognoa CEO Brent Vaughan. “The key benefit is it allows valuable employees to be happy and focused at work.”

The company built the parent-facing app to encourage early detection and intervention; the average age of an autism diagnosis is age 4, according to nonprofit Autism Speaks. An earlier diagnosis, says Vaughan, could be “the difference between attending special or normal schools” and could create a “lifelong change for a family.”

“We hear from parents constantly who are unable to keep a job,” says Wendy Fournier, president of the National Autism Association. “Many get frequent calls to pick up their kids from school, or have lots of medical appointments and need to take time off. It’s difficult for a lot of us to be dependable employees because caring for a child with autism can be volatile: Some days are fine, some are disastrous.”

Cognoa’s machine learning-based platform, which has been running for two years and has data from more than 140,000 children screened by the app, attempts to minimize the number of doctor’s visits that could leave an employee to take time off, says Vaughan.

Parents are asked to fill out a questionnaire that details their child’s play habits, eye contact, stomach and sleep problems, sensitivity to noise, and body and verbal language. They are also able to record videos of their children for a home-based, parent-selected evaluation, which is then compared to other videos and information in the system. The data is kept password protected and has rigorous data encryption that meet or exceed HIPAA compliance, Vaughan says.

“In the detailed assessments, parents receive descriptions of specific behavioral areas where their child is meeting developmental milestones, as well as areas that correspond with any elevated risk for delay,” he says. “The assessment reports also include the links to the videos the parent provided of the child’s actual behavior that corresponds with the assessment. We have found that both parents and clinicians find it valuable to see the videos of the child’s natural behavior at home.”

Vaughan says the app’s main competitor is standard care. However, not all pediatricians screen for developmental disorders, which is where the app bridges the gap in care for parents who might not be able to pay the co-pay or bring their child to the doctor’s office.

Archive

December 2016

20

Paroxysmal Nocturnal Hemoglobinuria Treatment Receives Fast Track Designation

RDR Staff; Published Online: Tuesday, Dec 20, 2016 Apellis Pharmaceuticals announced that their orphan drug APL-2, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) received Fast Track Designation by the FDA. APL-2 is designed for patients who experience hemolysis and require RBC transfusions even while taking eculizumab. APL-2 currently in two Phase Ib clinical trials. One trial assessing doses APL-2 administered by daily subcutaneous injection (SC) in patients with PNH who have not received the standard of care in the past, and the other is assessing doses of APL-2 as an add on with standard care. Results APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained through the dosing period. About APL-2 APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b, effectively blocking all three pathways of complement activation (classical, lectin, and alternative) with a particularly high potency against the alternative pathway.  About PNH Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder in which red blood cells break apart prematurely. It is an acquired hematopoietic stem cell disorder. Some hematopoietic stem cells in individuals with PNH are defective and consequently produce defective blood cells. These defective red blood cells of PNH are extremely susceptible to premature destruction by a particular part of a person’s own immune system called the complement system.  About Fast Track Designation  The FDA’s Fast Track program is designed to facilitate and expedite development and review of new drugs. Through the Fast Track program, a product may be eligible for priority review at the time of BLA and may be eligible to submit sections of the BLA on a rolling basis as data become available. APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained through the dosing period.

13

Green Biologics Begins Customer Shipments at First Commercial Plant

Little Falls, MN, facility produces 100 percent bio-based n-butanol and acetone Ashland, Virginia USA and Abingdon, Oxfordshire U.K. (December 13, 2016) – Green Biologics, Ltd., a UK industrial biotechnology and renewable specialty chemicals company, announced today the start of commercial shipments of bio-based n-butanol and acetone from its manufacturing facility in Little Falls, Minnesota. Over the past year, Green Biologics has built a robust pipeline of domestic and export customers combined with multiple partnerships to bring its products to downstream markets. These include distribution agreements with Acme Hardesty, Nexeo Solutions, and Caldic as well as a strategic partnership with HOC Industries, a custom blender, packager and distributor of consumer and government products. The company is collaborating with other industry leaders in a range of specialty markets and applications where performance and sustainability drive value. “The start of our first commercial facility is a critical milestone in building our position within the industry as a global renewable speciality chemicals company,” said Sean Sutcliffe,Chief Executive of Green Biologics. “We’re very proud to announce the start of shipments to key customers in highvalue markets and look forward to working with existing and new collaborators to bring a wide range of sustainable, environmentally-friendly products to shelves.” Offered as a high-performance, high purity, fully-sustainable alternative to conventional petrochemical-based commodities, Green Biologics’ speciality chemicalsaim to drive value in customer applications and downstream markets ranging from specialty coatings, pharmaceuticals, cosmetics, personal care and consumer products. Both butanol and acetone products carry the brand name BioPure™ and have receivedUSDA BioPreferred® status. As a member of the American Chemistry Council (ACC), Green Biologics’ commercial facility is actively working towards meeting Responsible Care® standards.

07

Cognito Therapeutics Launched with Exclusive License to Promising Alzheimer’s Research from The Massachusetts Institute of Technology

Boston, Mass. and San Francisco, Calif. — December 7, 2016 – Cognito Therapeutics announced today that the company has secured an exclusive worldwide license to the intellectual property developed from scientific discoveries by Li-Huei Tsai, Ph.D., and Ed Boyden, Ph.D., professors in the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology (MIT). The company was launched earlier this year with Series A financing from Morningside Venture. The scientific discoveries are featured in the December 8th issue of Nature. Working with mouse models of Alzheimer's disease, the team of scientists showed that by using a unique and totally non-invasive method of stimulation, they were able to restore gamma oscillation in the brains of the mice, which in turn activated the microglia cells to remove beta amyloid plaques in the brains. These plaques are characteristic of the brains of Alzheimer's disease patients, which are also deficient in gamma oscillation. “These results have opened up new doors to our understanding of Alzheimer’s,” said Prof. Tsai, Picower Professor of Neuroscience at MIT and co-founder of Cognito Therapeutics. “By demonstrating the underlying importance of these brain wave signatures, we have potentially uncovered a key to solving this disease in humans.” Tsai and Boyden co-founded Cognito Therapeutics to translate their findings into a treatment for Alzheimer’s patients. The company has filed an extensive portfolio of patents covering the applications of this novel approach to treating a variety of neurological disorders. "This is truly breakthrough science," said Gerald Chan, ScD, founder of Morningside and board member of Cognito Therapeutics. "It has the potential of being a game changer in our struggle to find an effective treatment for Alzheimer's disease. The social impact of such a treatment, if successful, would be enormous, as dementia is becoming the leading medical problem of an aging population." Cognito Therapeutics is based in Cambridge, Massachusetts, and at the San Francisco incubator TheraNova, a medical device developer with expertise in accelerating time-to-market for innovative medical technologies. “A device-based approach to Alzheimer’s is novel,” said Daniel Burnett, M.D., chief technology officer of Cognito Therapeutics and founder of TheraNova. “We are excited to be working with Morningside, which has shown an unwavering commitment to bringing this technology all the way into the clinic.”

05

ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS

• MIMESIS will accelerate and enable large scale development of ENYO Pharma’s novel discovery approach aimed at identifying new preclinical assets against infectious diseases and cancer from innovative drug discovery starting points inspired by viruses. Lyon, December 5, 2016 - ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate). The SME Instrument is part of Horizon 2020, the EU framework programme dedicated to innovation and research managed by the European Commission. It belongs to the pillar “Industrial Leadership” of H2020 and aims to support high growth and highly innovative SMEs with global ambitions. ENYO Pharma’s MIMESIS project applied for the June 2016 cut-off under the topic “Dedicated support to biotechnology SMEs closing the gap from lab to market”. MIMESIS has been selected by an independent jury of four experts recognised for their scientific and business expertise. The company will receive 2.5 M€ corresponding to the financing of 70% of the total project budget (€3.6 million). After a feasibility Phase that generated ENYO’s internal drug development programme on an autophagy target, MIMESIS will be expanded to an industrialised scale to accelerate the discovery of new therapeutic targets and innovative new chemical entities against infectious diseases and cancer. Dr Eric Meldrum, ENYO Pharma's Chief Scientific Officer commented, "We are very honoured to receive the recognition from the Horizon 2020 jury in what was a highly competitive process. MIMESIS represents a real paradigm shift in the development of new innovative drugs for pathologies where the medical need is immense. This financing will enable us to screen our library of original peptides and small molecules on hundreds of intracellular human targets previously untapped by the pharmaceutical industry.” For this project ENYO Pharma has designed a proprietary library of 10’000 small molecules to modulate host cell biology and also capable of disrupting protein:protein interactions (PPIs) between pathogens and the host. This library of developable chemical templates will be screened in phenotypic assays for inhibitors of the replication cycle of several viruses (Influenza, RSV, HRV, Zika) and a mycobacterium (TB). As this library is designed to modulate host cell biology, it will also be screened for inducers of Immunogenic Cell Death (ICD) in tumors. With €3.6 million over 24 months, most promising chemistries will be the starting point for numerous hit to lead optimisation programmes funded within the EU grant. Those optimisation efforts focused on novel intracellular targets will generate valuable Intellectual Property. Upon completion of MIMESIS, ENYO Pharma will further optimise its best chemical series either internally or in collaboration with other pharmaceutical companies up to clinical proof of concept. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 739086- MIMESIS

02

Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH

C3 inhibitor reduces hemolysis in patients with PNH, is generally well tolerated LOUISVILLE, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase Ib open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired, potentially lifethreatening disease characterized by complement-mediated hemolytic anemia. Interim results suggest that APL-2 reduces hemolysis in patients with PNH who receive daily subcutaneous injections of APL-2 as monotherapy or as an add-on to the standard of care, eculizumab. With APL-2 (270 mg) as monotherapy, three out of three (3/3) PNH patients achieved a reduction in lactate dehydrogenase (LDH) levels to below the standard for control in PNH (500 U/L). With APL-2 (270 mg) as add-on to eculizumab, six out of six (6/6) previously transfusion-dependent PNH patients did not require transfusions during the study and five out of six (5/6) PNH patients achieved hemoglobin levels within the normal range for healthy individuals. All 15 PNH patients who have been dosed across the two trials to date have completed at least one month of dosing, with five having received more than three months of dosing. Based on preliminary assessment, APL-2 is generally well tolerated. “Establishing that systemic inhibition of C3 is feasible with daily subcutaneous injections of APL-2 in patients with PNH is a significant achievement that validates C3 as a target in the complement pathway,” said Cedric Francois, M.D., Ph.D., chief executive officer of Apellis. “APL-2’s unique ability to target C3 and block all three pathways of the complement system is indicative of its potential to be an effective treatment for multiple complement-driven diseases. We are encouraged by the preliminary results APL-2 has demonstrated, as well as the favorable safety data observed thus far in the Phase Ib trials and our previous studies in healthy volunteers. All patients in the Phase Ib trials will have completed three months of dosing in January 2017.” Apellis will present the Phase Ib interim results today at the International PNH Interest Group (IPIG) Annual Scientific Assembly and will present the poster “APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers” tomorrow at the American Society of Hematology (ASH) Annual Meeting.

02

Why High School Students Should Seek Out Peer Mentors for College Applications

Find out how CollegeVine's near peer mentors can help high school students successfully apply for college. DEC 2, 2016 2:59PM EST -- When Ling Ritter applied early decision one of her top college choices, she had doubts about her ability to get in, but her guidance counselor told her she had a strong enough profile that the school would either accept or defer her, but not deny. So, when she received a rejection from that school, she was flummoxed. Ling, now 19, went back to that counselor who, this time, told her the rejection was an “indicator of [her] competitiveness,” and that she should remove any other “reach” schools she was planning to apply to. She didn’t listen. Instead, she added a few “safe” schools, and applied to her “reach” options as well — and was accepted to 13 out of 17, including Princeton University, where she’s currently a sophomore politics major. Ling’s college application process was rocky, perhaps in part because her main source of guidance was an adult counselor who was also responsible for helping out all of her classmates. After all, according to CollegeVine, the average public school student receives only 38 minutes with her school’s guidance department over the course of four years. But, Ling is determined to make it better for other high schoolers. She now works as a “Near-Peer Mentor” with CollegeVine, which pairs high schoolers with college students who not only still have the application process fresh in their minds, but also can lend insight on actual, current college life. As part of her one-on-one relationships with her mentees, Ling (who went through training with CollegeVine for the job) helps with their school selections, applications, and essays, managing deadlines and timelines, and more. And she’s not alone. CollegeVine’s college mentors attend schools around the country, and represent more than 20 different majors, extracurriculars, and individual experiences. We caught up with Ling to find out even more about the program — and why it’s awesome for both the mentors and the mentees. Teen Vogue: How do you think having a near-peer mentor would have changed your college application experience? Ling Ritter: Near-peer mentors help make college applications less of a guessing game. There is no silver bullet, no magic formula. However, after joining the CollegeVine team and going through their consultant training program, I now understand that there are ways mentors can help students authentically maximize their strengths in order to stand out in the applicant pool. TV: What do you wish a college student would have or could have told you during that process? LR: One piece of advice high school seniors frequently hear during the application process is, “Just be yourself.” I want to double down on that. You don’t need to be anyone else to succeed — you need to know that you are enough. But I also want to expand on this idea: Be yourself and understand who you are. Colleges are looking for individuals who demonstrate that they have been thinking about the intersections of their different identities, extracurricular interests, and academic pursuits, and that they are exploring how they can apply their unique perspectives to the world around them. An application is a very condensed representation of you, so seek out ways to add complexity and color. TV: As a mentor, what kind of advice do you give? What aspects of your college experience do you share? LR: Although [we follow a] curriculum, I will share anything about my college experience that my student wishes to know. CollegeVine’s pairing process is very specific, so I have thus far always been paired with a student who either is really interested in Princeton or has many shared passions in common with me (or both). This often leads to all sorts of great conversations [and questions, like], “Should I submit an arts supplement?” [or] “How do I begin to navigate the myriad career paths that stem from my interests?” TV: Do you have any moments from your mentoring experiences with high school students that especially stand out to you? LR: My favorite thing to hear from a student is, “Oh! I didn’t think I could do that.” Many students come in believing that college applications have to be weighty, and serious, and formal. While it’s important to demonstrate diligence, it’s equally important to convey personality. The times in which I was able to help students discover new and creative ways of expressing themselves, or showcasing quirky hobb[ies] that [don’t] fit within the confines of a traditional resume are definitely special moments for me. TV: What's the best part about being a near-peer mentor? LR: Getting to know my students has been incredible. They are all such kind hearted, multifaceted, and spirited individuals. I am rooting for them in their college searches, and I know that, when spring comes around, the tables will turn, and they will be the ones choosing college[s] that fill them with pride and excitement for the future. TV: How does mentoring high school students affect your current college life and path? LR: Mentoring gives my college life a sense of purpose. Being raised by immigrant grandparents instilled in me the importance of not only being thankful for the resources available to me, but also using those resources to help future generations obtain the same opportunities. CollegeVine gives me a platform to do so on a very personal level. TV: What about your confidence and outlook as a student and a person? LR: Working with CollegeVine has given me insight into some of the potential reasons...behind my own admittance to Princeton. This, coupled with hard work paying off in the classroom, has really helped me prove to myself that I belong here. TV: If you could give one piece of advice to students beginning the college application process, what would it be? LR: The weight of a hundred rejections is still less than that of refusing to try and always wondering if things could be different. Rub some dirt on it and get back to being awesome.

November 2016

30

MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4

HAYWARD, Calif. and SHANGHAI, China – November 30, 2016 – MicuRx Pharmaceuticals, Inc. today announced the start of a Phase 1 clinical trial of a new antimicrobial agent, MRX-4, for the treatment of infections caused by Gram-positive bacteria including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE). MRX-4 is a prodrug form of the oral antibiotic MRX-1, presently in Phase 3 clinical trials in China for the treatment of complicated skin infections.

This comprehensive Phase 1 trial, now enrolling patients at a single center in the United States, will evaluate safety, tolerability, pharmacokinetics and bioavailability of the oral formulation of MRX-4. The study will enroll 122 healthy subjects in nine single- and four multiple-ascending dose cohorts. Concurrently, the safety, tolerability, and pharmacokinetics of the intravenous formulation of MRX-4 will be evaluated in 60 healthy subjects of five single- and four multiple-ascending dose cohorts, along with an oral to IV crossover study.

“We anticipate that success in this Phase 1 trial would enable a rapid transition into advanced clinical studies in the U.S. for this new means of efficient delivery of our antibiotic systemically,” stated Zhengyu Yuan, Ph.D., president and CEO of MicuRx.

MRX-1 is a next-generation oxazolidinone agent that has shown notably improved hematopoietic safety compared to first-generation antibiotics, such as linezolid, while maintaining excellent efficacy characteristics for this class. The prodrug form of MRX-1, named MRX-4, serves to expand its utility into both intravenous and enhanced oral applications.

29

Green Biologics Receives USDA Certification

Renewable Specialty Chemicals Company Receives Certification Under USDA BioPreferred® Program Ashland, Virginia and Abingdon, Oxfordshire U.K. (November 29, 2016) – Green Biologics, Inc., the U.S. subsidiary of Green Biologics Ltd., a U.K. industrial biotechnology and renewable chemicals company, announced today that its high purity bio-based n-butanol and acetone have received official certification under the USDA BioPreferred® program. The products are now certified as 100 percent bio-based and are marketed under the BioPure™ brand. “Having our n-butanol and acetone named as USDA Certified BioBased Products is yet another milestone that we can point to when demonstrating the value and differentiation of our products from conventional petrochemical-based commodities,” said David Anderson, Global Vice President of Marketing for Green Biologics.

18

Stealth BioTherapeutics Announces Positive Phase 2 Clinical Trial Findings for Patients Undergoing Renal Angioplasty

Data support company’s cardiorenal program, including three ongoing heart failure trials

Single elamipretide infusion improves kidney microvasculature and function after renal artery angioplasty

BOSTON – November 18, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today presented results from the EVOLVE trial, which demonstrated that a single dose of elamipretide prior to renal artery angioplasty and stenting procedures improved kidney function and blood flow for three months post-procedure. The data were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2016 in Chicago.

“Patients undergoing renal angioplasty and stenting, intended to open up kidney arteries blocked by atherosclerosis, often fail to regain normal kidney function due to tissue damage during the procedure, possibly due to the sudden replenishment of oxygen to starved tissues,” said Dr. Stephen Textor, the principal investigator for the trial. “The study results validate our preclinical findings and our underlying hypothesis that elamipretide may help prevent acute kidney injury by preserving mitochondrial function in cells and ultimately improve measures of kidney function in these patients.”

15

SKSpruce Technologies Finalist WBA Awards

San Jose, CA, November 15, 2016—SKSpruce Technologies, an emerging Silicon Valley leader in carrier-class Wi-Fi, is a finalist for the Wireless Broadband Alliance (WBA) “Best Next Gen Wi-Fi Network Infrastructure” award, recognizing and celebrating excellence in wireless innovation. The WBA recently announced the shortlist for its annual WBA Industry Awards 2016, taking place at the Wireless Global Congress, November 16-17 in San Jose, California. The finalist entry recognizes SKSpruce’s Wi-Fi solution used in the largest integrated Wi-Fi/cellular system in the world, deployed in Japan by SoftBank, a leading global carrier with more than 100 million subscribers. The SoftBank Mobile Wi-Fi system has 460,000 access points throughout the country seamlessly integrated into their 4G LTE network providing transparent uninterrupted handover between 4G LTE and Wi-Fi, delivering a superior user experience. SoftBank Mobile’s entire Wi-Fi network is controlled by the SKSpruce SKG10000 gateway, and its integration to the core mobile network is provided by SKSpruce.

14

Stealth BioTherapeutics Initiates Phase 1 Study of Elamipretide in Dry Age-Related Macular Degeneration

Top-line data from study evaluating elamipretide in patients with dry age-related macular degeneration expected mid-year 2017

BOSTON – November 14, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of ReCLAIM, a Phase 1 study evaluating elamipretide in intermediate age-related macular degeneration (AMD). Top-line data are expected mid-year 2017.

“There are currently no FDA-approved treatment options for dry AMD, so we are eager to better understand the effect that elamipretide may have in treating these roughly 13 million patients,” said Dr. Scott Cousins, the trial investigator, and Professor of Ophthalmology and Director of the Duke University Center for Macular Diseases. “Mitochondrial dysfunction that stems from various environmental toxins may be an important causative factor in dry AMD, and in laboratory models, elamipretide appears to prevent mitochondrial dysfunction in the retinal pigment epithelium.”

ReCLAIM is an open-label study to evaluate the safety and tolerability of 12 weeks’ treatment with daily subcutaneous injections of elamipretide in patients, age 55 and above who have at least one eye with intermediate AMD, and have either: a) high-risk protein deposits (drusen) on the retina without any geographic atrophy (GA), a characteristic of advanced AMD which can result in the loss of photoreceptor cells or b) GA with an unaffected central fovea (noncentral GA). The study’s primary endpoints are safety and tolerability, and the secondary endpoints are changes from baseline in physical/ophthalmic examinations and feasibility of subcutaneous injections in this patient population.

“ReCLAIM will build upon our ongoing ophthalmic program to help us better understand the potential of elamipretide to treat back of the eye diseases as well as the effects of the treatment to slow the aging process in eye tissue,” said Stealth Chief Executive Officer Reenie McCarthy. “We look forward to evaluating initial results of this study mid-year 2017.”

08

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

Houston, TX – November 8, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of Florida, Gainesville to develop a novel oncolytic virus platform.  The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers.

A major advantage of the myxoma virus is its ability to attach to T lymphocytes and other white blood cells, which are then delivered to the patient to trigger tumor cell killing and antitumor immunity.  Myxoma virus can be armed with multiple immune stimulatory genes, a feature shared by other large DNA virus such as herpes simplex and adenovirus.

“The myxoma virus has unique properties for attacking cancer,” said CEO Frank Tufaro, Ph.D. “We think this technology platform provides a new modality for delivery of a potent oncolytic virus to tumors by co-administering it along with T cells.  We look forward to testing this “Trojan horse” strategy in the clinic.”

“The myxoma virus is a novel oncolytic candidate that does not infect normal human cells but has a unique ability to identify the damaged signaling pathways found in the majority of human cancers; thus, resulting in productive infections in the patient’s cancer cells,” stated Grant McFadden, Ph.D., Professor in the Department of Molecular Genetics & Microbiology at the University of Florida, College of Medicine.

07

Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

Late-breaking poster presents data from elamipretide clinical trial in chronic kidney disease patients at risk of acute kidney injury

BOSTON – November 7, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that the abstract, “Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis” has been accepted as a late-breaking clinical trial poster at the American Society of Nephrology (ASN) Kidney Week 2016 taking place in Chicago, November 15-20, 2016.

“The EVOLVE trial underscores our commitment to our cardiorenal program,” said Stealth’s Chief Executive Officer Reenie McCarthy. “We are pleased to present the details of these results both in the context of our three ongoing Phase 2 heart failure studies, as well as to inform our approach to other diseases of aging in which mitochondrial dysfunction is a contributing factor.”

EVOLVE was a double-blind, placebo-controlled study that evaluated 14 patients ages 40 to 80 with chronic kidney disease (CKD) at risk of acute kidney injury (AKI). The primary endpoint was change in kidney function, and the secondary endpoint was a change in renal blood flow and cortical perfusion.

02

CollegeVine Secures $3.1 Million In Series A Funding

CAMBRIDGE, Mass., Nov. 2, 2016 /PRNewswire/ -- CollegeVine, the fast-growing EdTech startup specializing in high school mentoring for college applications, has closed a $3.1 million Series A funding round led by Morningside Technology Ventures ("Morningside") with participation by New York-based University Ventures. Morningside is a private equity and venture capital firm. Gerald Chan, its co-founder, has joined CollegeVine's Board of Directors. University Ventures is a specialty venture capital fund that exclusively focuses on promising ideas in the higher education space. The announcement was made today by Jon Carson, the CEO of CollegeVine. CollegeVine was started by two Harvard University students and one University of Chicago student working out of the Harvard iLab. The company uses a near peer model of matching talented college students with high schoolers to help them with the college application process. CollegeVine's services quickly earned a reputation for its outstanding college admissions results. Two years ago, the company employed 20 college students as consultants; today it employs almost 300. "There is a huge unmet need for high school students to get proper guidance and mentoring in their planning for college and their application for admission. The fast growth of CollegeVine's business validates that its services are exactly what high school students are looking for. Optimizing the college application process is beneficial both to the applicants and to the universities," said Chan. "With the backing of Morningside and support from University Ventures, we are now positioned to grow the company to meet consumer demand. We plan to use the Series A investment to build out our technology platform and product suite, grow the team, and accelerate our growth," said Carson. "We are pleased to have Gerald join our Board as he has been a valued partner and mentor over several ventures. I am honored, to be working with him on another new and exciting EdTech venture." Morningside was the primary backer of FamilyEducation Network where Carson was both the founder and CEO. FamilyEducation Network became the largest K-12 online network when it was acquired by Pearson Plc for $175 million in 2000. CollegeVine has recently strengthened its management team with the addition of former Zipcar executive Doug Williams as chief technical advisor and Harvard Business School professor Deepak Malhotra as a member of the board of directors.

01

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

Houston, TX – November 1, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been treated in a multicenter Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent glioblastoma.

The CAPTIVE trial is evaluating the potential effect of DNX-2401 and KEYTRUDA in patients with recurrent glioblastoma, a disease for which there is neither a cure nor adequate treatment. Leading medical centers in the United States and Canada are participating.

DNX-2401 is a potent conditionally replicative oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response.

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.  This activity enhances the T cell response and leads to effective tumor destruction. KEYTRUDA is currently approved in the United States for advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and advanced head and neck squamous cell cancer (HNSCC).

“Glioblastoma is a difficult disease to treat with conventional therapies,” said Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix. “Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease.”

October 2016

31

Myanmar HTI Project Formally Launched

October, 2016 - SKSpruce Technologies formally launched the Myanmar Carrier-grade Wi-Fi project. A dedicated project team led by Henry Wu (VP of Product, SE & Product Marketing) was set up to ensure the smooth implementation of this project. The project marks the inaugural collaboration between SKSpruce and Myanmar HTI. Aimed at providing excellent data communication services and comprehensively improving user experience, the project will deploy the world-class carrier-grade Wi-Fi solution of SKSpruce in major areas of Yangon. During this project, over ten thousand APs will be deployed in 22 towns (10 towns in phase I) of Yangon to provide Wi-Fi services to 6 million Yangon citizens, in order to improve the data communication capacity of Yangon public areas, and to bring great economic profits and social benefits to Myanmar. Myanmar HTI project is SKSpruce’s largest project in Southeast Asia this year. Meanwhile, it indicates that SKSpruce is making a significant move to expand Southeast Asian market. SKSpruce is attracting an increasing number of international clients with its continuous product innovation, solution optimization, and technology development.

25

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Patients Hospitalized with Congestive Heart Failure

Top-line results anticipated in second half of 2017

BOSTON – October 25, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction associated with common diseases of aging and genetic mitochondrial diseases, today announced the initiation of IDDEA-HF, a Phase 2 study evaluating elamipretide in patients hospitalized due to congestive heart failure. Heart failure causes more than two million hospitalizations in the U.S. and Europe each year.

“In heart failure, mitochondrial dysfunction may not only be a causative factor, but may also contribute to the progression of the disease and the associated fluid build-up that causes congestion, due to muscle weakness from a lack of energy production,” said Stealth Vice President of Clinical Development Jim Carr. “In line with our findings in elderly patients enrolled in the   trial, we hope to demonstrate the ability of elamipretide to increase energy production to help the heart muscle work better, subsequently relieving congestion in the body.”

IDDEA-HF is a randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of daily treatment with elamipretide in patients who have been hospitalized with congestive heart failure. Up to 300 patients will be randomized within 72 hours of presentation to receive 20 mg daily elamipretide or placebo intravenously for up to seven days. The primary endpoint is change in NT-proBNP, a cardiac biomarker reflecting the level of congestion. Secondary endpoints include change in clinical status and safety and tolerability.

“IDDEA-HF is a key step in our development of therapies for common diseases of aging. These patients have failed current therapies, experiencing an episode of acute decompensation, which highlights the intense need for new options within the heart failure treatment paradigm where we believe elamipretide can have a significant impact,” said Stealth Chief Executive Officer, Reenie McCarthy. “The data from this study, together with our other ongoing trials in heart failure, will help inform our projected Phase 3 heart failure program as well as our approach to other common diseases of aging for which elamipretide may have therapeutic potential.”

17

ENVISIA THERAPEUTICS RELEASES ENV515 (travoprost XR) PHASE 2 DATA SHOWING NINE-MONTH DURATION OF ACTION AFTER A SINGLE DOSE IN PATIENTS WITH GLAUCOMA

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients RESEARCH TRIANGLE PARK, NC – OCTOBER 17, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. “ENV515 continues to show great potential with a favorable safety profile and a sustained, clinically meaningful reduction in IOP over the initial nine months,” said Benjamin Yerxa, President of Envisia. “We plan to initiate enrollment in a new cohort of this phase 2 trial by year-end, which will enable us to evaluate the high dosage form of ENV515 that has been formulated with the goal of achieving efficacy comparable to TRAVATAN Z® with a duration greater than 9 months.”

12

New app helps workers track child development, identify autism early

By Amanda Eisenberg, Published October 12 2016, 1:41am EDT --

As employers struggle with retention rates across the board, healthcare technology company Cognoa is trying to keep a specific population employed: parents of children with developmental disorders.

The Palo Alto-based company recently launched Cognoa for Employers, a mobile app that screens children as young as 18 months for developmental disorders, to assist with early detection and cut down on future healthcare costs and missed workdays. The app would be included in a benefits package for parents to assess how their young children are reaching developmental benchmarks and screens for autism, speech delays and ADHD.

With one in six children in the United States diagnosed with a developmental disorder, according to the Centers for Disease Control and Prevention, the impact affects parents who work full-time.

“There is a greater pressure on one of the parents to leave the workforce and stay home with the child,” says Cognoa CEO Brent Vaughan. “The key benefit is it allows valuable employees to be happy and focused at work.” The company built the parent-facing app to encourage early detection and intervention; the average age of an autism diagnosis is age 4, according to nonprofit Autism Speaks. An earlier diagnosis, says Vaughan, could be “the difference between attending special or normal schools” and could create a “lifelong change for a family.”

“We hear from parents constantly who are unable to keep a job,” says Wendy Fournier, president of the National Autism Association. “Many get frequent calls to pick up their kids from school, or have lots of medical appointments and need to take time off. It’s difficult for a lot of us to be dependable employees because caring for a child with autism can be volatile: Some days are fine, some are disastrous.”

Cognoa’s machine learning-based platform, which has been running for two years and has data from more than 140,000 children screened by the app, attempts to minimize the number of doctor’s visits that could leave an employee to take time off, says Vaughan.

Parents are asked to fill out a questionnaire that details their child’s play habits, eye contact, stomach and sleep problems, sensitivity to noise, and body and verbal language. They are also able to record videos of their children for a home-based, parent-selected evaluation, which is then compared to other videos and information in the system. The data is kept password protected and has rigorous data encryption that meet or exceed HIPAA compliance, Vaughan says.

“In the detailed assessments, parents receive descriptions of specific behavioral areas where their child is meeting developmental milestones, as well as areas that correspond with any elevated risk for delay,” he says. “The assessment reports also include the links to the videos the parent provided of the child’s actual behavior that corresponds with the assessment. We have found that both parents and clinicians find it valuable to see the videos of the child’s natural behavior at home.”

Vaughan says the app’s main competitor is standard care. However, not all pediatricians screen for developmental disorders, which is where the app bridges the gap in care for parents who might not be able to pay the co-pay or bring their child to the doctor’s office.

September 2016

28

ACD Launches BaseScope™ Suite of Tissue Analysis Assays Enabling Breakthrough Advances in Molecular Pathology

The BaseScope assay is unique in enabling spatial localization of splice variants, point mutations and highly homologous sequences within tissue samples NEWARK, Calif., Sept. 28, 2016 /PRNewswire/ -- Advanced Cell Diagnostics (ACD), a brand of Bio-Techne Corporation, announces the release of a breakthrough RNA in situ hybridization (ISH) assay delivering the unprecedented capability of detecting RNA transcripts at single base resolution. The BaseScope™ assay is available commercially as a kit for use in laboratories worldwide and via ACD's Pharma Assay Services. As one of the offerings of the Pharma Assay Services portfolio, BaseScope provides highly sensitive and specific detection of exon junction/splice variants, SNPs, small insertions/deletions, and short targets, including complex and highly homologous gene families such as MAGE and ILT in just four weeks. Dr. Yuling Luo, Founder and President of ACD, explained the significance of the launch: "BaseScope is a truly revolutionary assay providing groundbreaking insights into biological and disease mechanisms not possible with other technologies – again demonstrating our pioneering position in molecular pathology. Before the launch of the BaseScope assay, it was simply not possible to detect a specific exon-exon junction or a point mutation in situ with morphological context."

27

Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitors to Increase Antitumor Efficacy

BERKELEY, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted two posters presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-AACR) in New York. The preclinical data demonstrate positive changes in the tumor microenvironment and induction of a tumor-specific immune response by Aduro’s LADD (listeria-based immunotherapy construct) and STING (Stimulator of Interferon Genes) Pathway Activator immunotherapy platform technologies. Importantly, adding a PD-1 blockade to either immunotherapy regimen significantly bolstered antitumor efficacy. “These preclinical data demonstrate the underlying mechanisms by which our LADD and STING immunotherapy platforms activate the immune system and induce robust innate immunity, facilitating a change in the tumor microenvironment which results in effective destruction of cancer cells in several preclinical models,” said Thomas Dubensky, Jr., Ph.D., chief scientific officer of Aduro. “Importantly, the combination data are even more impressive, showing increased efficacy when our LADD and STING platforms are combined with an anti-PD1 checkpoint inhibitor to combat the tumor’s ability to hide from the immune system. These data support our strategy to combine our immunotherapy regimens with checkpoint inhibitors for greater anti-tumor activity, looking toward the ultimate goal of better, more effective patient care.”

26

MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I

Funds to Support Phase 3 Clinical Trials in U.S. and China HAYWARD, Calif. and SHANGHAI, Sept. 26, 2016 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. today announced the close of its $55 million Series C financing. Led by GP Healthcare Capital, the round included new investors GP TMT Capital, 3E Bioventures Capital, and Delian Capital. Mr. Yu Miao of GP Healthcare Capital will join the board of directors. "Our investors have recognized the unique benefits that our next-generation antibiotic, MRX-I, offers to patients who need better tolerated, more convenient oral and intravenous antibiotics to treat MRSA," commented Zhengyu Yuan, Ph.D., president and CEO of MicuRx. "We are very pleased to have the solid support of such a strong syndicate which will fund MicuRx through our first New Drug Application (NDA) filing in China. The fast growing pharmaceuticals market in China, presents an excellent opportunity for MRX-I. In parallel, we are pursuing development in the U.S. and other global markets." Funding from Series C financing will be used to continue development of MRX-I in both the United States and China. With the funds, the company expects to complete its Phase 3 trial using oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China, complete one pivotal US Phase 3 trial with oral and intravenous formulations of the drug for the indication of acute bacterial skin and skin structure infections (ABSSSI) as well as file a Chinese NDA for cSSSI. The BFC group provided financial advice to MicuRx.

19

Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly

Trial evaluating treatment with investigational drug, elamipretide, demonstrated improved mitochondrial function by increasing energy production after single treatment BOSTON – September 19, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced results from the MOTION Trial. This clinical trial evaluated the systemic delivery of elamipretide on skeletal muscle function in elderly subjects with reduced mitochondrial function, and demonstrated improved mitochondrial energy production after treatment. This increase in mitochondrial bioenergetics was comparable to the improvement resulting from six months of exercise training, shown in a similar patient population in other trials. The data from this trial were presented at the Late Breaker Poster Session of the Heart Failure Society of America Annual Scientific Meeting in Orlando, Florida on Saturday, September 17. MOTION was a Phase 2 randomized, double-blind, placebo-controlled study that evaluated 40 patients ages 60-85 with demonstrated mitochondrial dysfunction to determine the effect of elamipretide on skeletal muscle energetics and performance. The primary endpoint showed improved mitochondrial energy production (ATPmax) which increased by 30% over baseline as compared to a 10% change in the placebo group (p=0.055). The improved bioenergetics were associated with greater skeletal muscle function (p=0.004). Furthermore elamipretide was well tolerated with no treatment-emergent adverse events (TEAEs) identified.

13

Kezar Life Sciences Announces Initiation of Phase 1 Clinical Program for Lead Candidate KZR-616, a First-in-Class Immunoproteasome Inhibitor

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 /PRNewswire/ -- Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis, announced today the initiation of its Phase 1 randomized, double-blind clinical program for KZR-616, a selective inhibitor of the immunoproteasome. Since enrollment of the first cohort on August 9, Kezar has completed dosing of 24 subjects across three cohorts in the single ascending dose (SAD) portion of the Company's Phase 1a study, which includes both SAD and multiple ascending dose (MAD) portions. The study is expected to enroll a total of 64-80 subjects, with key endpoints including pharmacokinetics and biomarkers of target engagement, as well as safety and tolerability. In the Phase 1 program, KZR-616 is administered once-weekly as a subcutaneous injection. Pending progress of the study, the Company anticipates that it will report topline pharmacokinetics, safety, and target engagement data by the end of 2016. Additionally, in the first half of 2017 the Company anticipates commencing a Phase 1b study of KZR-616, which is expected to enroll up to 40 patients with autoimmune disorders and include a cohort with a placebo control. "We are proud to be the first company to move a selective inhibitor of the immunoproteasome into the clinic," said John Fowler, Kezar's Chief Executive Officer and Co-Founder. "The Kezar scientific team is unparalleled in its understanding of the unique biology and therapeutic potential of the immunoproteasome, and has done a tremendous job moving our lead program rapidly into the clinic.  We look forward to demonstrating the safety profile and target engagement of KZR-616 in the coming months, and launching Phase 1b and 2 trials in patients in 2017."

12

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease

Study will evaluate the long-term safety, tolerability and efficacy of elamipretide in patients who completed the Phase 2 MMPOWER study BOSTON – September 12, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of a longitudinal extension trial for evaluating elamipretide in primary mitochondrial disease. The study, MMPOWER-2, will be limited to patients who completed the initial MMPOWER Phase 2 study. Positive data from MMPOWER were announced in June 2016 showing statistically significant improvement in distance walked in six minutes. “Patients with rare primary mitochondrial diseases have no FDA-approved treatment options to address their needs,” said Stealth Chief Executive Officer Reenie McCarthy. “We’re committed to helping fill these significant gaps in care through our study of elamipretide. Following the promising results from our Phase 2 MMPOWER study, we’re happy to announce the initiation of MMPOWER-2, which will help us better understand the effects of longer treatment with elamipretide for these patients, who often face severe challenges completing even simple daily activities.” MMPOWER-2 is a randomized, double-blind, placebo-controlled crossover study to evaluate the safety, tolerability and efficacy of four weeks’ treatment with once-daily subcutaneous injections of elamipretide in patients with genetically confirmed mitochondrial disease. All patients in this study have previously completed the MMPOWER study.

01

ASLAN PHARMACEUTICALS AND A*STAR ENTER RON ANTIBODY LICENSING AND RESEARCH COLLABORATION AGREEMENT

Singapore, 1 September 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the licensing of a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR) which ASLAN will develop and commercialise worldwide. RON is a receptor tyrosine kinase, and an overexpression of RON leads to increased tumour metastasis. Consequently, RON activation in tumour cells promotes aggressive disease. The RON antibody licensed by ASLAN was developed by A*STAR’s p53 Laboratory and is currently in preclinical development. The antibody has demonstrated preclinical efficacy in a range of in vivo models of human cancer. Under the terms of the agreement, ASLAN will gain global rights to develop the RON antibody and intends to commence clinical studies in 2018. Commercial terms were not disclosed. To further advance the project towards clinical trials, ASLAN and A*STAR have also entered a three-year research collaboration. ASLAN will be responsible for the design of innovative clinical development programmes, in close collaboration with A*STAR’s p53 Laboratory which will continue to be responsible for the preclinical development of the antibody assets.

August 2016

31

InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias

San Francisco, California, August 31, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by delivering medications via the inhalation route, today announced that it has initiated a Phase 1 clinical trial for its lead product intended to treat recent onset atrial fibrillation (AF). The single-center trial will evaluate the safety and tolerability of inhaled flecainide in a randomized, double-blind, placebo-controlled design consisting of single ascending doses of inhaled active solution, or inhaled placebo solution, in multiple cohorts of healthy volunteers. This study is being conducted at CMAX, a division of IDT Australia. “This is an important step in advancing InCarda’s lead product into clinical development,” stated Narsi Rangachari, co-founder and chief operating officer of InCarda Therapeutics. “With its novel delivery approach, InCarda is uniquely positioned to develop this rapid-onset treatment for patients with paroxysmal AF.”

23

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

ENDPOINTS NEWS - It’s not often that two recent college grads can come up with enough cash and connections to run a Phase II study of a new combination drug for a tough and deadly disease like ALS. But with some backing by biotech legend Henri Termeer and $8 million in venture cash and grant money, Justin Klee and Josh Cohen say they’re ready to turn what started out as an undergraduate science project at Brown into a clinical reality in a matter of months at a startup dubbed Amylyx. The key component in all this, the money to start dosing patients, comes from a $5 million Series A led by Morningside Venture with contributions from the ALS Investment Fund and former Genzyme CEO Termeer. Combined with a $3 million grant from the ALS Accelerated Therapeutics Initiative and some discount pricing from a network of hospitals engaged in ALS work, and Klee and Cohen say they’ve reached the threshold of a mid-stage trial that will look for both efficacy and safety data. “It is atypical,” Klee allows in our telephone interview this morning. But the two young entrepreneurs are preparing to take a shot at ALS on a budget that most Big Pharmas would spend on preclinical work. And they say their work could have applications for Alzheimer’s, another devastating disease that has so far burned billions of dollars in largely wasted research efforts.

22

Amylyx Nabs $5M to Take Aim at Nerve Cell Death in ALS Patients

Xconomy Boston - While the cause of amyotrophic lateral sclerosis, or ALS, remains a mystery, many researchers are trying to develop a cure by stopping its effect—the death of nerve cells that leads to muscle deterioration and the patient’s eventual death. One Cambridge, MA-based drug developer, Amylyx Pharmaceuticals, has received a $5 million Series A financing to take its nerve cell-targeting treatment, AMX0035, into a Phase 2 trial for ALS patients. The treatment is a combination of sodium phenylbutyrate, a drug commonly used to remove ammonia from the body, and tauroursodeoxycholic acid, a derivative of stomach bile acid. With the two drugs combined into one, the company believes it can possibly block nerve cell death and neurotoxic inflammation, two potential causes of ALS. The company expects the trial to begin in late 2016 or early 2017. The funding was provided by Morningside Venture, the ALS Investment Fund, and former Genzyme CEO Henri Termeer. Since selling Genzyme to Sanofi for $20 billion in 2011, Termeer has been an active investor and advisor to startup biotechs, including Moderna Therapeutics, Lysosomal Therapeutics, Aura Biosciences, and X4 Pharmaceuticals. The $5 million funding follows a $3 million grant for the Phase 2 trial that Amylyx received from the ALS Accelerated Therapeutics Initiative, which is a collaboration between the ALS Association and ALS Finding a Cure. Amylyx says it has raised $10 million for its drug, called AMYX0035.

22

Amylyx Announces $5 Million Series A Financing to Support Phase II Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Inc. announced today that it has completed a $5 million Series A financing to support its upcoming Phase II trial in patients with Amyotrophic Lateral Sclerosis (ALS). Morningside Venture led the financing and was joined by the ALS Investment Fund and former Genzyme CEO Henri Termeer, as well as new and previous private investors. The financing adds to a recently awarded $2.96 million grant to support the clinical trial from the ALS Accelerated Therapeutics Initiative, which is a collaboration between the ALS Association and ALS Finding a Cure. Overall, Amylyx has raised $10 million in grant funding and private financing to advance AMX0035. The IND for this Phase II trial is on schedule for the fourth quarter of 2016 and the trial will start shortly thereafter. Over 20 clinical sites across the United States have already expressed interest in participating.

10

BRISTOL-MYERS SQUIBB REACQUIRES RIGHTS TO ASLAN002 (BMS777607) IN ASIA FROM ASLAN

Agreement validates ASLAN’s strategy and development capabilities Singapore, 10 August 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, today announced that Bristol-Myers Squibb will reacquire the rights to ASLAN002 (BMS777607) in China, Australia, Korea, Taiwan and other Asian territories. ASLAN002 is a potent small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. ASLAN in-licensed ASLAN002 in the above-mentioned markets from Bristol-Myers Squibb in November 2011 and has successfully completed a phase 1 study, in which ASLAN002 was shown to be safe and well tolerated. The phase 1 data demonstrated that inhibition of RON resulted in potent inhibition of plasma biomarkers of RON activity. ASLAN will receive an upfront payment of US$10 million and is eligible to receive development and regulatory milestones in excess of US$50 million. In addition, ASLAN is eligible to receive royalty payments on future worldwide sales of ASLAN002. Bristol-Myers Squibb resumes responsibility for all development and commercialisation activities and expenses. Commenting on the agreement, Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: “The acquisition of ASLAN002 by Bristol-Myers Squibb supports ASLAN’s strategy to in-license investigational programmes and apply the unique development expertise of our team to accelerate the generation of high-quality data and significantly increase the value of a programme. The commercial terms of the agreement further strengthen ASLAN’s financial position following the closing of our recent financing rounds; we are in a very strong position to continue to build our proprietary pipeline of novel clinical programmes.”

08

Green Biologics: Selling commodities as specialties

August 8, 2016 - Industrial biotechnology company Green Biologics Ltd. (GBL; Abingdon, United Kingdom) produces n-butanol and acetone by fermenting sugars from renewable feedstocks. The two products are drop-in alternatives to petroleum-based chemicals and find use in a variety of applications. Although n-butanol and acetone are typical examples of commodity chemicals, sold on volume and price, GBL is effectively selling its versions of the products as specialties. “What I think is interesting around Green Biologics is how we are developing a specialty chemicals market in what is effectively a commodities space,” says Sean Sutcliffe, CEO at GBL. “We’re not really competing with our friends at BASF [SE] or Dow [Chemical Co]. They focus on volume, price, and supply chains. We’re focusing on similar molecules but on a different sector entirely, where it’s performance and downstream value that count.” The company’s objective is to apply synthetic biology and modern process technology to the clostridium microbial fermentation process to develop and produce renewable biobased products. “It’s a specialty chemicals business but with perhaps a stronger intellectual property [(IP)] base than usual,” says Sutcliffe. ”Our IP base is particularly strong in this sector, with the technology underpinning the strategy. Our key strategy is bringing specialty chemical applications that provide a mixture of higher performance and natural ingredients ... . There is a strong market drive towards green, natural, sustainable ingredients.” GBL says that its competitive advantage straddles the biology, the process, right through to the end market. “Our business model is that we develop the technology; we own, operate, make, and sell the product, and work [closely] with customers,” Sutcliffe says.

04

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

Houston, TX – August 4, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million research grant from the FDA’s Office of Orphan Products Development to support its Phase 2 clinical trial evaluating DNX-2401 with the checkpoint inhibitor pembrolizumab for patients with recurrent glioblastoma. This FDA grant program supports the development of medicines for rare diseases or conditions where no current therapy exists. Approximately 100 applications are received per year from which roughly 10 are selected for funding following rigorous scientific review. DNX-2401 is a potent oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies in patients with recurrent glioblastoma and gynecologic cancer have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response. DNX-2401 has already received Orphan Drug Designation and Fast Track Designation by the FDA and PRIME Designation by the EMA. Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix said, “We are delighted by the FDA’s continued recognition of DNX-2401 as a promising treatment for glioblastoma by awarding this grant to further support our product development strategy. This is an important accomplishment for the company and another significant step toward bringing DNX-2401 to patients with devastating brain tumors.”

01

Corn-to-Butanols Project On Track

The renewables group aims to ramp up production from its US facility through 2017 as it looks for partners for further expansions Will Beacham, Barcelona - 1-14 August, 2016 - Green Biologics, the UK-headquartered producer of renewable-based n-butanol and acetone, is on track to complete the retrofit of a commercial scale US ethanol facility by the end of 2016, its CEO Sean Sutcliffe says. The company set out plans at the beginning of 2015 to retrofit the 21m gallon ethanol facility at Little Falls, Minnesota, for the production of high-purity n-butanol and acetone, and the project is progressing on schedule, according to Sutcliffe. The company also has a 1/30 scale demonstration plant that has been running since August 2014 to prove its Clostridium microbial fermentation technology and ensure consistent quality is deliverable. This allows high-purity n-butanol and acetone to be produced, which is benzene-free and with low water content compared to petrochemical-derived alternatives, he claims. “We’ve had interest from people looking for these advantages. One major producer of butanol derivatives said it’s the best quality they’d ever sampled. People are rightly cautious as they need high-quality product,” he adds.

01

Bio-Techne Corporation Completed its Acquistition of Advanced Cell Diagnostics

MINNEAPOLIS, August 01, 2016 / PRNewswire/ –– Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents the 9th acquisition for Bio-Techne in the last three years. With these acquisitions, Minneapolis-based Bio-Techne has grown from approximately 650 employees in 2013 to nearly 1,700 staff worldwide and has expanded its global reach with subsidiaries in every major geographic market. Organically, we continue to develop and launch in excess of 1,500 new products to market on a yearly basis which enable researchers to address new and more complex questions in the life science field. This latest acquisition of ACD is consistent with our strategic plan, which includes both organic growth and acquisitions that fill portfolio gaps.

July 2016

27

DNAtrix Receives European Medicines Agency PRIME Designation

Houston, TX – July 27, 2016 – DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for DNX-2401 as a promising new treatment for recurrent glioblastoma. The PRIME initiative was launched by the EMA in March of 2016 to accelerate the regulatory approval of breakthrough therapies that target an unmet medical need. By offering prompt interaction with Sponsors developing innovative therapies, the objective is to provide patients who have few treatment options with early access to priority medicines that could provide significant benefit. DNX-2401 is a potent oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies in patients with recurrent glioblastoma and gynecologic cancer have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response. “We are pleased and honored that the European Medicines Agency has recognized the potential of our oncolytic immunotherapy DNX-2401 to make a positive impact on glioblastoma,” said Joanna Peterkin, M.D., M.S., Chief Medical Officer of DNAtrix. “We look forward to working with the EMA on this important development program for DNX-2401, with the goal of improving the quality of life of patients with brain tumors.”

21

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone’s MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

Houston, TX & Lowell, MA – July 21, 2016 – DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced the successful intratumoral administration of DNX-2401 with the Alcyone MEMS Cannula (AMC) to patients with recurrent glioblastoma. A substudy is being performed as part of a larger multicenter study to evaluate DNX-2401 as treatment for recurrent glioblastoma, a disease for which there is neither a cure nor adequate treatment. DNX-2401 is a potent oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies in patients with recurrent glioblastoma and gynecologic cancer have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response. The AMC is a dual-lumen MRI-safe neuro-ventricular cannula with the smallest-in-class micro-tip and patented design features that ensure optimal and consistent drug distribution while eliminating backflow. Analysis of intraoperative MRI from the pilot study demonstrates that the AMC delivers DNX-2401 precisely and accurately into the tumor. Neurosurgeons participating in the study have also praised the cannula’s ease of use. “The Alcyone MEMS Cannula is a compelling technology that ensures a complete dose of DNX-2401 is delivered directly to the brain tumor and provides a standard, reliable and consistent method of virus administration. We are excited to incorporate this technical advantage into our development program to combat this devastating disease,” said Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix.

11

2020 On-site Optometry Raises $3 Million, Plans for Rapid Growth

BOSTON--(BUSINESS WIRE)--2020 On-site Optometry raised $3 million in an extension to its Series A-1, bringing 2020 On-site’s total fundraising to $7.9 million. 2020 On-site, a Boston-based start-up, delivers comprehensive vision care (eye exams, glasses, contacts) to offices and schools via their state-of-the-art mobile vision centers (MVCs). 2020 is the U.S.’s largest provider of mobile vision centers for corporate wellness, with more than 10,000 exams performed on a 2020 MVC at over 230 corporations. This fundraising round includes investments from Morningside Ventures; Andrew Balson, CEO of Match Beyond; John Connolly, Senior Advisor of Bain Capital Ventures; RoAnn Costin, Board Member of Lululemon Athletica; Lee Linden, former Head of Commerce of Facebook; Mark Nunnelly, former Managing Director of Bain Capital; and David Sanderson, Partner of Bain & Co; among others. When asked why he invested in 2020, Mr. Balson commented, “2020 has solved a problem for companies and their employees by providing high-quality optometry in a convenient and low-cost setting. We will see more MVCs parked at companies and more eyes cared for as the 2020 team grows their presence. This is investing in a company that will do well by doing good.” On-site eye exams are becoming a new standard in corporate wellness at a time when companies are looking for ways to drive employee engagement and help employees stay on top of their health. Operating in Boston and Atlanta today, 2020 launches in Chicago this fall.

07

Bio-Techne to Acquire Advanced Cell Diagnostics for Up to $325M

Bio-Techne said it has agreed to acquire molecular pathology test developer Advanced Cell Diagnostics (ACD) for up to $325 million in a deal that expands the buyer’s offerings into genomics technology, as well as its presence within clinical labs. Founded in 2006 by President and CEO Yuling Luo, Ph.D., and COO Steve Chen, Ph.D., ACD develops cell- and tissue-based diagnostic tests for personalized medicine. ACD’s products and services are based on its proprietary RNA in situ hybridization, or RNA ISH, technology, a proprietary target hybridization and signal amplification technology enabling the detection of single RNA molecules in single cells and commercialized under the RNAscope® brand name. According to ACD, RNA ISH could provide pathologists with reagents capable of specifically detecting transcripts of expressed genes, noncoding RNAs, as well as more subtle genetic details, such as gene splice variants, gene fusions, copy number variations, and single-nucleotide polymorphisms. “With broader adoption of the technology in the diagnostic arena, it has the potential to revolutionize the choice of reagents in diagnostic practices, such as oncology, infectious diseases, and others,” Bio-Techne President and CEO Charles R. Kummeth said in a statement. “As we continue to expand the portfolio of products and technologies we bring to our customers, we view the leading-edge ACD products as a natural and complementary extension of the Bio-Techne product offering.”

06

BIO-TECHNE ANNOUNCES AGREEMENT TO ACQUIRE ADVANCED CELL DIAGNOSTICS

Minneapolis/July 6, 2016/--Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 million due upon the achievement of certain milestones. The transaction is expected to close on or about August 1, 2016, with closing subject to the satisfaction of customary closing conditions. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition. Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne, commented, “We are very pleased to have ACD as part of Bio-Techne Corporation. First of all, ACD marks Bio-Techne’s entry into the genomics field and market. Second, and more importantly, its innovative and versatile technology has the potential to change pathology practices. RNA-ISH is a transformative technology facilitating and improving the monitoring of gene expression patterns at the single cell level––while retaining the morphological context of the tissue being analyzed. ACD’s technology serves both research and diagnostic markets, expanding Bio-Techne’s presence in the clinical lab setting. With broader adoption of the technology in the diagnostic arena, it has the potential to revolutionize the choice of reagents in diagnostic practices, such as oncology, infectious diseases and others. As we continue to expand the portfolio of products and technologies we bring to our customers, we view the leading-edge ACD products as a natural and complementary extension of the Bio-Techne product offering, with the ultimate goal to more completely address our customers’ varied needs in the research and clinical space."

June 2016

29

Argos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 Financing

DURHAM, N.C., June 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it had completed the closing of the second tranche of its private placement financing under the Company's previously announced March 2016 securities purchase agreement. In the closing of the second tranche, Argos sold, for a total purchase price of $29,824,520, a total of 5,478,672 shares of common stock and warrants to purchase a total of 4,109,005 shares of common stock (0.75 shares of common stock for each share of common stock purchased), based on a purchase price per share of common stock and accompanying warrant equal to $5.44375. The closing of the second tranche was triggered by the previously announced recommendation from the Company's independent data monitoring committee ("IDMC") that the Company continue its pivotal ADAPT Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma based on results of the IDMC's scheduled interim data review.

28

Luqa Pharmaceuticals and Daewoong Pharmaceuticals to launch a Strategic Collaboration in the Aesthetics Field

June 28, 2016 - Luqa Pharmaceuticals, a China specialty company, has announced it has signed a Letter of Intent with leading Korean company Daewoong Pharmaceuticals for the commercialization and promotion of innovative products in the aesthetics field. Through this collaboration, Daewoong will continue the ambitious international expansion of its aesthetics portfolio, building on landmark agreements with leading companies in Europe, USA and Latin America. In words of Mr. Robert Braithwaite, CEO of Luqa Pharma: “We look forward to this collaboration with Daewong to continue to expand our aesthetics portfolio for Greater China. Daweong’s high quality products are a perfect complement to our current range therapies, allowing us to provide a complete range of solutions for dermatologists, aesthetics doctors and our patients.”

27

Stealth BioTherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide for the Treatment of Heart Failure

Trials to evaluate potential treatment option for heart failure patients with either reduced or preserved ejection fraction BOSTON – June 27, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of two Phase 2 studies evaluating elamipretide in heart failure: PROGRESS-HF in patients with heart failure with reduced ejection fraction and RESTORE-HF in those with preserved ejection fraction. Top-line data from each are expected in the second half of 2017. “The heart’s reduced ability to relax and contract during heart failure may be linked to mitochondrial dysfunction and a resulting lack of energy in heart muscle,” said Stealth Vice President of Clinical Development Jim Carr. “Since muscle is required for both pumping and re-filling the heart, we believe elamipretide could address this lack of energy in the heart muscle in the two major forms of heart failure by improving mitochondrial function.” “Our initiation of these Phase 2 trials marks an important milestone for Stealth and the progression of our cardiorenal program for elamipretide. Following the promising findings from our Phase 1 PREVIEW trial in heart failure, we hope to demonstrate improvements in heart function across both types of heart failure with longer-term dosing,” said Stealth Chief Executive Officer Reenie McCarthy.

24

NPIC Achieves SQF Level 2 Certification

Dallas, TX — NPIC is proud to announce that they have increased their grade of SQF certification. This grade increase comes after an in-depth audit process which took place in May of 2016. The audit consisted of a thorough review of all processes, including training, sanitation and manufacturing. The SQF audit process is run by the SQF Institute, an organization that sets the standard for food manufacturers in the United States, Canada and Mexico. Their mission is “to deliver consistent, globally recognized food safety and quality certification programs based on sound scientific principles, consistently applied across all industry sectors and valued by all stakeholders.” The SQF program is recognized by retailers and food service providers around the world and is the only program of its kind that integrates a quality component as well as food safety.

23

Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor

LOUISVILLE, Ky., June 23, 2016 /PRNewswire/ -- Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous injection in healthy adult volunteers. Forty subjects were administered APL-2 subcutaneously (SC) either as a single dose (ranging from 45 to 1,440mg) or repeated doses for 28 consecutive days (ranging from 30 to 270 mg/day). Both studies concluded that pharmacological doses of APL-2 were safe and well tolerated and that APL-2's PK / PD profile supports daily SC administration. In addition, complement-mediated hemolysis (destruction of the red blood cells) was assessed and daily APL-2 doses of 180mg and 270mg significantly reduced hemolytic activity as early as eight days after the start of dosing, and this inhibition was maintained throughout the dosing period. "We are pleased to have accomplished this major milestone in the clinical development of APL-2. Targeting C3 is very challenging as it is the most abundant complement protein in the body. It is the first time that a study demonstrates that inhibiting complement at the C3 level can be safely achieved in a clinical study," said Cedric Francois, M.D., Ph.D., Chief Executive Officer of Apellis.

17

Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial

Positive Phase 2 data in rare disease trial lead to extension study and planning for Phase 3 BOSTON – June 17, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the presentation of positive results from MMPOWER, a Phase 2 trial evaluating the systemic delivery of elamipretide for the treatment of primary mitochondrial myopathy, or muscle weakness, in patients with a genetically confirmed mitochondrial disease. The findings demonstrated statistically significant improvements with elamipretide in distance walked in six minutes, the study’s primary efficacy endpoint and an accepted measurement of functional exercise capacity. The results were presented at Mitochondrial Medicine 2016, the United Mitochondrial Disease Foundation (UMDF) symposium, in Seattle at 8:10 a.m. PT. “The muscle weakness, exercise intolerance and heightened fatigue experienced by patients with primary mitochondrial disease can make simple daily tasks very challenging,” said Dr. Amel Karaa, trial investigator, internist and clinical geneticist at Massachusetts General Hospital. “These findings demonstrate the potential for elamipretide to help improve their ability to perform everyday activities. We look forward to further study of this compound in upcoming trials of primary mitochondrial disease.”

13

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review

DURHAM, N.C., June 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that the independent data monitoring committee (IDMC) for the Company's pivotal Phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) has recommended the continuation of the trial based on results of the IDMC's scheduled interim data review. The next IDMC meeting is being planned to coincide with the Genitourinary Cancers Symposium in February 2017. "As the largest global Phase 3 trial ever performed in newly diagnosed, intermediate and poor risk mRCC patients, the ADAPT trial continues to progress," said Dr. Robert Figlin, the Steven Spielberg Family chair in hematology oncology, professor of medicine and biomedical sciences at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the co-principal investigator for the ADAPT trial. "With all the excitement regarding the clinical benefit of the emerging immuno-oncology therapies, a positive outcome of the ADAPT trial, because of AGS-003's novel mechanism of action, could be a game changer in the treatment of mRCC." AGS-003 is an individualized immunotherapy that captures both mutated and variant antigens that are unique to each patient's tumor, and, therefore, specifically designed to induce an immune response targeting that patient's particular tumor antigens. In an open-label Phase 2 trial, treatment with AGS-003 plus sunitinib resulted in median overall survival of more than 30 months in newly diagnosed, intermediate and poor risk mRCC patients. We have enrolled a total of 462 mRCC patients in our ongoing pivotal, randomized Phase 3 ADAPT trial evaluating AGS-003 in combination with standard targeted therapy, which has a primary endpoint of overall survival. AGS-003 is Argos' most advanced Arcelis®-based product candidate.

08

Are Shipping Containers the Future of Farming?

The startup Freight Farms is using repurposed freight containers and LED lights to grow acres’ worth of produce in a fraction of the space. Inside the cavernous interior of a former Boston-area taxi depot—walls covered in graffiti, pools of water on the concrete floors—three gleaming green-and-white containers sit side by side. The steel boxes are former “reefers”—refrigerated shipping containers used to transport cold goods. Bone-chilling rain is falling outside, but inside the 320-square-foot boxes, it’s a relatively balmy 63 degrees, and the humid air is heavy with the earthy smell of greens. Filling each box are 256 neat vertical towers of plants, bathed in a noonday-intense pink light. The crops being cultivated here—lettuce, herbs and other leafy greens—are not what we’ve come to expect from this kind of operation. But the company behind this agricultural innovation owes a large debt to America’s pot farmers. Freight Farms was founded in 2010, its existence predicated on a bet that LEDs would soon become efficient enough for farming as if the sun had disappeared—without breaking the bank. Co-founder Brad McNamara puts it this way: “Traditional research said, yeah, LEDs are good, but the more important research was that they were improving at a Moore’s-Law rate.” Moore’s Law, used to describe the exponential increase in computing power over the past 50 years, can be applied to LEDs thanks in part to the needs—and considerable resources—of marijuana growers. In addition to 128 LED strips, each “farm” has a water circulation system, 8 gallon-size tanks of liquid fertilizer and a propane tank for producing supplemental CO2—all running on as little as 10 gallons of water and 80 kWh of energy per day. Under the right conditions, a grower can go from seeds to sellable produce within six weeks. According to data pooled by the company, an average Freight Farms box can produce 48,568 marketable mini-heads of lettuce a year—the growing power of two acres of farmland. Freight Farms is part of a rapidly expanding field: Food and agricultural technology startups received $4.6 billion in investment in 2015, almost double the $2.36 billion that poured into the sector in 2014, according to a report from agriculture investment platform AgFunder. Companies like John Deere and Monsanto have long invested in new technology for conventional farming, but we’re now seeing a disruption of farming itself.

08

VOICEBOX LAUNCHES NEXTGEN VOICE AI FOR AUTO MAKERS

Fully Integrated Software Development Kit v5.0 Provides Platform for Superior In-Car Voice Systems Detroit, MI (June 8, 2016)__VoiceBox Technologies, the award-winning innovator of Contextual Natural Language Understanding (CNLU) and next gen Voice Artificial Intelligence (AI) announced the new VoiceBox Automotive Software Development Kit (v5.0), now available for Windows, Linux and Android platforms. With full integration of the VoiceBox Embedded Automatic Speech Recognition (ASR) engine and the company’s patented context management, VoiceBox continues to offer auto makers a single solution for powering the next generation of in-car voice systems. The company’s Automotive SDK is the first of its kind to offer Deep Neural Networks (DNN) which enables the processing of complex, contextual conversations. It is also the only Voice AI technology to include parallel hybrid processing with machine learning. This allows user queries to be simultaneously processed in both embedded and cloud systems to optimize the delivery of results. “The new VoiceBox Platform is a reflection of our technology’s continuous evolution, and features the natural and personal VoiceBox AI experience by leveraging DNN processing, machine learning, and patented hybrid architecture,” said Rich Kennewick, President and Cofounder of VoiceBox.

07

InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors

San Francisco, California, June 7, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company’s board of directors. Dr. Bischofberger has spent over 25 years at Gilead Sciences, where he currently serves as the company’s chief scientific officer and executive vice president of research and development. “Dr. Bischofberger has been a key driver of Gilead’s success, and we’re very pleased to have his unique acumen and insights advising InCarda on product and pipeline development,” said Grace E. Colon, Ph.D., President and Chief Executive Officer of InCarda Therapeutics. “We are deeply honored to have him join our Board and help guide InCarda as a developer of paradigm-shifting therapies for cardiovascular conditions.” “InCarda has an exciting therapy for atrial fibrillation and a novel approach that I believe has potential to significantly improve the treatment of acute cardiac conditions. I look forward to contributing to the development of important medications by this promising company,” stated Dr. Bischofberger.

06

NuCana’s Acelarin achieves high clinical activity and durable disease control in patients with recurrent ovarian cancer

Synergy with carboplatin and positive Phase 1b data presented at ASCO 2016 Chicago, IL, 6th June 2016: NuCana today presented positive interim results of a Phase 1b clinical study of Acelarin (NUC-1031) in combination with carboplatin in patients with late-stage recurrent ovarian cancer at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). NuCana is a clinical stage biopharmaceutical company developing and commercializing a portfolio of novel anti-cancer medicines based on their proprietary ProTide technology. Acelarin is NuCana’s first ProTide to be advanced into the clinic and a range of new anti-cancer agents are being developed from this platform technology. ProTides represent a new class of medicines capable of bypassing specific drug resistance mechanisms and generating high intracellular levels of the anti-cancer agent in tumour cells. At ASCO today the Phase 1b study results were presented from the first 22 patients, of which 20 were evaluable. Significant clinical activity was achieved with an overall response rate of 30%, including 1 (5%) complete response, 5 (25%) partial responses and 13 (65%) with stable disease. The overall disease control rate was 95%, which was durable, with a progression free survival already at 6.6 months and ongoing. The Acelarin combination was well tolerated and no unexpected adverse events were reported.

06

Stealth BioTherapeutics Reports Positive Results for Primary Mitochondrial Myopathy Trial

Trial evaluating treatment with elamipretide in rare disease meets efficacy and safety endpoints Data to be presented at Mitochondrial Medicine 2016 on Friday, June 17 at 8:10 a.m. PT BOSTON – June 6, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced positive results from MMPOWER, a Phase 2 trial evaluating the systemic delivery of elamipretide for the treatment of primary mitochondrial myopathy, or muscle weakness, in patients with a genetically confirmed mitochondrial disease. Data from the MMPOWER trial will be presented at , the United Mitochondrial Disease Foundation (UMDF) symposium, on Friday, June 17 at 8:10 a.m. PT.

04

Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO

BERKELEY, Calif., June 04, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of updated data from an ongoing Phase 1b clinical trial of its immunotherapy product candidate CRS-207 in combination with pemetrexed and cisplatin (standard of care chemotherapy) as front-line treatment for patients with unresectable malignant pleural mesothelioma (MPM). The results from the first of two cohorts were presented today in a poster presentation at the 2016 American Society of Clinical Oncology Meeting (ASCO) held in Chicago. Of the 36 evaluable patients, disease control was observed in 94% (34/36), including 3% (1/36) with a complete response, 56% (20/36) with partial responses and 36% (13/36) experiencing stable disease following treatment with CRS-207 and chemotherapy. Prior to receiving chemotherapy, 31% (11/36) of patients experienced some tumor shrinkage (range: -1% to -43%) after receiving CRS-207 alone. The estimated median overall survival was 16.4 months (95% CI: 11.0 – 20.6 months). CRS-207 was generally well-tolerated with no treatment-related serious adverse events or cumulative toxicities when administered with chemotherapy. "The observed responses with the combination of CRS-207 and standard chemotherapy are unprecedented in mesothelioma," said Dean Fennell, Ph.D., F.R.C.P., professor of Thoracic Medical Oncology at the University of Leicester and president of the International Mesothelioma Interest Group (iMig). "Pleural mesothelioma is a devastating disease, and these data suggest that immunotherapy has the potential to advance treatment options for these patients." Dirk G. Brockstedt, Ph.D., executive vice president of Research and Development at Aduro added, "These results demonstrate that CRS-207 induces anti-tumor activity in patients with malignant pleural mesothelioma. We are looking forward to the results from the study’s second cohort, which is evaluating the addition of immune modulating doses of cyclophosphamide to the CRS-207 chemotherapy combination. Preclinical data suggest that the simultaneous inhibition of regulatory T-cells through the addition of a checkpoint inhibitor may amplify the tumor response and overall survival seen with CRS-207. As such, the combination of CRS-207 with a checkpoint inhibitor could be the regimen we advance in our mesothelioma program going forward.”

01

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber’s Hereditary Optic Neuropathy

Trial augments ongoing clinical development program for rare genetic mitochondrial diseases BOSTON – June 01, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, today announced the initiation of ReSIGHT, a phase 2 clinical study evaluating the topical eye drop delivery of elamipretide (formerly known as Ocuvia) for the treatment of patients with Leber’s Hereditary Optic Neuropathy (LHON). Affecting approximately 35,000 people worldwide, LHON is an inherited mitochondrial disease that causes central vision loss stemming from the damage to retinal ganglion cells due to dysfunction of energy-producing complexes in the mitochondria. The disease, which can lead to legal blindness, affects more men than women and often strikes patients in their late teens and early 20s. “Elamipretide offers hope for patients suffering from this rare ophthalmic disease, for which there is no FDA-approved treatment. The loss of vision can be sudden and devastating, often occurring in both eyes within a few weeks’ time. Unfortunately, the resulting vision loss is usually permanent, underscoring the desperate need for effective treatment options,” said Alfredo Sadun, M.D., Ph.D., UCLA Doheny Eye Institute, the primary investigator for the study.

May 2016

19

Edyn debuts smart water valve to put home gardens on autopilot

Oakland, Calif.-based Edyn started selling a new, smart gardening device this week: an Internet-connected water valve that lets users irrigate their gardens or lawns automatically. The Edyn Water Valve uses data from the company’s Edyn Garden Sensor, a soil sensor, along with local weather systems, to adjust the moisture levels in the soil. If a user wants, they can adjust their irrigation systems via the Edyn smartphone app. Sold for $69, the Edyn Water Valve weighs less than eight ounces, is solar-powered, Wi-Fi-enabled and fits a standard garden hose. The Edyn system was designed to be small enough for use with a hose that’s connected to a kitchen sink, and a window box garden if desired.

12

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors

BERKELEY, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient has been dosed in a Phase 1 trial for ADU-S100 (also known as MIW815), a novel STING (Stimulator of Interferon Genes) pathway activator. Activation of the STING pathway in tumors has been shown to be a critical step to initiate an innate response that may lead to a systemic adaptive tumor-specific immune response. Novartis, Aduro’s collaborator for STING pathway activator compounds in the field of oncology, is conducting the study. The achievement of this milestone triggers a $35 million milestone payment from Novartis to Aduro. “We are thrilled to embark on this landmark Phase 1 study, which we believe is the first clinical trial to specifically target the STING pathway. ADU-S100 (MIW815) has the potential to induce an anti-tumor immune response that is unique to the treated individual, an approach that potentially offers the benefits of a personalized therapy but using an off-the-shelf small molecule,” said Thomas Dubensky, Jr., Ph.D., chief scientific officer of Aduro. “ADU-S100 is the first compound to enter the clinic under our collaboration with Novartis, and through this Phase 1 study, we look forward to gaining insight into the safety, tolerability and initial efficacy for several different types of cancer. We have now advanced two differentiated immuno-oncology platforms into the clinic: ADU-S100, with the start of this trial, and our LADD listeria-based immunotherapy strains in clinical studies in multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma.”

03

Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma

RESEARCH TRIANGLE PARK, NC – May 3, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). ENV515, the Company’s lead product candidate, is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. “We are excited to report positive results for the low dosage form of ENV515, which demonstrated a favorable safety profile and a sustained, clinically meaningful reduction in IOP over the entire three months,” said Benjamin Yerxa, President of Envisia. “These results enable us to move forward with the dose escalation study later this year, evaluating the high dosage form of ENV515 that has been formulated with the goal of achieving efficacy comparable to TRAVATAN Z with a duration greater than six months.” Previously, a 28-day evaluation of the low dosage form of ENV515 demonstrated a reduction in IOP comparable to topical timolol, while the high dosage form of ENV515 demonstrated results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution). This second cohort of the ongoing phase 2 trial was a 12-month safety and efficacy evaluation of the low dosage form of ENV515 that was designed as an open-label trial that enrolled five glaucoma patients at sites within the U.S. The low dosage form of ENV515, administered once on Day 1, achieved the interim efficacy endpoint in this 3-month analysis, time-matched 8 AM IOP over the three-month post-dose period, with -7.1 mmHg or -27% change from IOP baseline that was comparable to topical timolol 0.5% twice daily with -7.4 mmHg or -28% change from IOP baseline, administered to the non-study eye. ENV515 was well tolerated and there were no serious adverse events, no changes in corneal endothelial cell counts evaluated by an independent reading center, and no changes in corneal thickness. The most common adverse event was early-onset transient hyperemia,oreye redness,related to the dosing procedure. “Envisia’s extended delivery approach, leading to sustained IOP control without any loss of efficacy over time, may dramatically change the way we treat glaucoma in the majority of our patients,” said Dr. Thomas Walters, MD, the lead investigator for cohort 2 of the ENV515 phase 2 trial. “The current results position Envisia as one of the leaders in the field of ophthalmology.”

03

BioScale Announces Company Name Change to ProterixBio and New Focus on Pulmonary Diagnostics and Disease Management

Billerica, MA, May 3, 2016 – BioScale, Inc. today announced that the company is changing its name to ProterixBio, Inc. The name change reflects a new strategic direction centered on high value clinical applications including diagnostics products and disease management services. ProterixBio is developing innovative products to transform the management of chronic diseases, with the initial applications focusing on pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis and idiopathic pulmonary fibrosis (IPF).

April 2016

28

Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma

Studies Demonstrated that BION-1301 anti-APRIL Monoclonal Antibody Blocks Multiple Myeloma Cell Proliferation, Drug Resistance and Immunosuppression in the Tumor Microenvironment BERKELEY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the publication of a pivotal paper elucidating the roles of B cell maturation antigen (BCMA) and its ligand A PRoliferation-Inducing Ligand (APRIL) in multiple myeloma, highlighting the potential of its proprietary monoclonal antibody (mAb) BION-1301 targeting APRIL. The authors demonstrated through in vivo and in vitro preclinical studies that the APRIL/BCMA ligand/receptor pair drives multiple myeloma tumor growth and survival, and activates immunosuppressive mechanisms that allow the tumor to thrive. Importantly, the studies demonstrated that BION-1301 halts tumor growth and overcomes drug resistance to chemotherapeutic agents lenalidomide and bortezomib in preclinical models. The study, entitled “APRIL and BCMA promote human multiple myeloma growth, chemoresistance, and immunosuppression in the bone marrow microenvironment,” was published by Kenneth Anderson, M.D. Ph.D., and Yu-Tzu Tai, Ph.D. of the Dana-Farber Cancer Institute. The article appears online ahead of print in the peer-reviewed journal Blood. “For the first time, we have identified several different molecular mechanisms by which APRIL activates BCMA to promote multiple myeloma progression in vivo,” said Dr. Anderson, program director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber and Kraft Family Professor of Medicine at Harvard Medical School. “Understanding the mechanism of tumor progression and resistance allowed us to test a novel approach to potentially combat disease advancement by using an anti-APRIL antibody. BION-1301 blocks the APRIL-induced signal cascade at a critical juncture, and represents a new potential mechanism to both achieve disease response and restore immune function, even in patients with myeloma resistant to current therapies.”

20

Genocea Congratulates Dr. George Siber, 2016 Albert B. Sabin Gold Medal Award Recipient

CAMBRIDGE, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Dr. George R. Siber, board member and chair of Genocea's scientific advisory boards, on being awarded the 2016 Albert B. Sabin Gold Medal Award by the Sabin Vaccine Institute. The award recognizes his research contributions in the development of innovative vaccines, including the first pneumococcal conjugate vaccine, the first meningococcal conjugate vaccine and the first antibody for the prevention of RSV infections. He was also involved in development of the first rotavirus vaccine and live attenuated influenza vaccine. This prestigious honor — the highest scientific honor granted by the Sabin Vaccine Institute and one of the most important in the field of vaccinology — is awarded annually to a distinguished member of the public health community who has pioneered work in vaccinology or a complementary field. "We have been fortunate over the years to benefit from George's leadership and expertise, and congratulate him on this very well deserved honor," commented Chip Clark, president and chief executive officer of Genocea. "The impact on humanity of the vaccines he has helped to develop has been profound and his contributions to the scientific community and to the body of knowledge about vaccine development will continue to have a positive impact on the lives of millions of patients."

18

InSilixa Developing Drug-Resistance TB Test Showcasing Potential for Hundreds of Targets

Apr 18, 2016 | Madeleine Johnson -- The TB test is intended to showcase the firm’s core technology, which can perform highly multiplexed nucleic acid amplification and analysis of hundreds of targets simultaneously. InSilixa received a two-year, $1.5 million Phase II Small Business Innovation and Research grant from the National Human Genome Research Institute in 2013. The company also received $224,764 in funding from the National Institutes of Health last month to develop a point-of-care test for cancer-causing strains of human papillomavirus. In addition to a total of about $3 million in NIH funding overall, InSilixa has won $1.4 million in early seed funding and completed a $13 million Series A financing round in 2014. The firm is now seeking $35 million in Series B funding. InSilixa CEO Arjang Hassibi told GenomeWeb in an interview that the general area of focus for the firm’s technology is infectious diseases. Specifically, the firm is exploring “applications in which you require an actionable test in a quick amount of time … a complex test looking at drug resistivity with different strains, where the level of multiplexing is beyond simple PCR platforms that are out there.” The InSilixa technology uses semi-conductor-based chips for solid-phase array-based detection as the amplification is happening. It’s not a microarray, but it overcomes a bottleneck other technologies encounter with the detection step of NAAT testing, Hassibi said. “The problem of multiplex PCR has been you can always increase the level of multiplexing — the record for sequencing is up to a few thousand — so, you can create multiple amplifications, but the challenge is detecting them in parallel,” he said. By using optical methods, with different colors and channels for detection, other technologies can multiplex to a certain level. But, Hassibi said, commercial multiplex panels often divide samples and do multiple reactions to get the required number of targets. InSilixa’s method instead uses multiplex PCR to amplify all the regions in which mutations exist in one reaction chamber, and then it uses a CMOS, or complementary metal-oxide semiconductor, chip to capture and detect during the reaction, and perform a melt curve analysis in parallel. The melt curve component is able to distinguish single-base pair changes and provides “the sensitivity of sequencing,” Hassibi said. The firm’s first chip, the Hydra 1K, can examine 1,024 mutations in parallel, and the company envisions this technology will be unique in the white space between sequencing and individual PCR tests or small multiplex PCR panels.

07

Green Biologics Selects Nexeo Solutions as its U.S. Distribution Partner

Logistics and Distribution Key Focus of Renewables Collaboration Ashland, Virginia and Abingdon, Oxfordshire U.K. (April 7, 2016) – Green Biologics, Inc., the U.S. subsidiary of Green Biologics Ltd., a U.K. industrial biotechnology and renewable chemicals company, announced today a distribution agreement with Nexeo Solutions, a Texas (U.S.) based global distribution company. Nexeo Solutions will become Green Biologics’ national distributor of renewable n-butanol and acetone to U.S. customers in a number of key markets including CASE (coatings, adhesives, sealants and elastomers), HI&I (household, industrial & institutional cleaners), PCI (personal care intermediates) and energy chemicals. “Nexeo Solutions is a superb partner for Green Biologics,” said Timothy G. Staub, Global Vice President of Business Development for Green Biologics. “With decades of distribution experience, particularly in high value solvents, Nexeo Solutions brings a unique combination of logistical capabilities and market knowledge along with a critical presence both in key markets and geographies important to our customers.” Green Biologics is currently constructing its first commercial production facility for renewable n-butanol and acetone in Little Falls, Minn., and aims to start up the plant in late 2016 with shipments to customers by Q4. Green Biologics is a new member of the American Chemistry Council (ACC) and is building its new green solvents facility to meet Responsible Care™ standards.

05

InCarda Therapeutics Appoints Dr. Luiz Belardinelli as Chief Medical Officer

San Francisco, California, April 5, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced that the company has appointed Luiz Belardinelli, M.D., to the position of Chief Medical Officer. Dr. Belardinelli joins InCarda for this position half-time and plans to also continue in his role at Gilead Sciences where he serves as a Senior Advisor for the Cardiovascular Therapeutic Area of Gilead. Previously Luiz was Senior Vice President for Cardiovascular Therapeutics for Gilead. He brings highly relevant cardiovascular experience having been a major contributor to the discovery and development of three cardiovascular products, Adenocard, Lexiscan and Ranexa. “We are thrilled to have Dr. Belardinelli join our team. As a recognized global expert in cardiac arrhythmias (such as atrial fibrillation) we will benefit from his preclinical and clinical knowledge and regulatory experience—both in the U.S. and abroad—as well as his vast network of colleagues in this space,” stated Grace E. Colon, Ph.D., President and Chief Executive Officer of InCarda. “Dr. Belardinelli joins us at an important time, as we are on track to initiate a Phase 1 clinical trial in Q2 of this year to evaluate our inhaled formulation of flecainide for treatment of patients with recent onset paroxysmal atrial fibrillation.”

03

Stealth BioTherapeutics announces presentation of elamipretide data at ACC. Trial results support further study of elamipretide in heart failure.

BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced promising results from the Phase 1 PREVIEW trial evaluating elamipretide (formerly known as Bendavia) in heart failure patients with reduced ejection fraction. The results showed elamipretide to be safe and well tolerated with demonstrated improvements in key secondary efficacy measures. The data were presented today at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago during the Novel Therapies in Heart Failure moderated poster session, South Hall A1, from 12:30-1:45 PM CT. Heart failure affects approximately six million people in the U.S. and continues to be the leading cause of hospitalization, despite available therapies. “The heart requires a significant amount of energy to both contract and relax, and targeting the mitochondrial dysfunction affecting the heart’s energy supply in this population is a new approach to treating the disease,” said Melissa Daubert, M.D., Duke University Health System and the trial’s primary investigator for echocardiography. “Based on the improvement in heart function seen after just one high-dose treatment, we are very excited to explore the benefits of elamipretide after repeated dosing.”

March 2016

31

Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing

CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was safe and well tolerated by patients, with no serious adverse events related to the vaccine in the trial. "We are very pleased with these data, which show that GEN-003 has strong and durable effects on both HSV-2 viral activity and genital herpes clinical disease, supporting our belief that GEN-003 could become a cornerstone treatment for patients affected by this serious disease. Specifically, a single course of treatment of GEN-003 may offer benefits similar to a full year of daily administration of oral antivirals - but with greatly improved convenience," said Chip Clark, president and chief executive officer of Genocea. "We anticipate reporting virologic efficacy data for GEN-003 from our recently-initiated Phase 2b study in the third quarter of 2016, clinical efficacy data at 6 months post dosing around the end of 2016 and conducting our end of Phase 2 meeting with the FDA in the first quarter of 2017." "These 12 month data highlight the potential of GEN-003 to significantly enhance the genital herpes treatment landscape," said Lori A. Panther, M.D., MPH, infectious diseases specialist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School. "Because of the physical and psychological impact of this disease, both patients and treating physicians would be eager to use an effective treatment that more conveniently improves control of outbreaks. The reduction in viral shedding, which is thought to cause the epidemic spread of genital herpes, is also encouraging."

29

VoiceBox Launches New Offering To Enable In-Car Digital Assistants

Mar 29, 2016 - New Technology for Automobile Manufacturers Simplifies Development of Superior In-Car Voice Systems VoiceBox Technologies, a global provider of contextual voice and natural language understanding (NLU) technologies for automotive, mobile and IoT products, today announced the availability of the company’s new Embedded Automatic Speech Recognition (ASR) product for automotive applications. Integrated with the company’s award-winning NLU technology, VoiceBox’s Embedded ASR now offers auto makers a single solution for powering the next generation of in-car voice systems. “In-car systems have long been held back by their lack of available alternatives in ASR software,” said Tom Freeman, SVP of Kymeta Corporation which was recently showcased at the North American International Auto Show. “By providing their DNN enhanced ASR together with their superior NLU, VoiceBox now offers Automotive companies the opportunity to advance their in-car solutions to better meet the voice experience consumers want.” Designed to convert speech into text, which is then processed through NLU, VoiceBox’s Embedded ASR supports more than 20 languages. The company’s Embedded ASR solution is the first of its kind to offer Deep Neural Networks (DNN) which enable the processing of complex, contextual conversations. It is also the only ASR technology to include parallel hybrid processing with machine learning. This allows user queries to be simultaneously processed in both embedded and cloud systems to optimize the delivery of results. VoiceBox’s Embedded ASR technology is available now for use in automotive information and entertainment units and is also used in VoiceBox mobile and IoT solutions.

28

Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Research Initiative

BERKELEY, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- The University of California (UC) Berkeley, in collaboration with Aduro Biotech, Inc. (Nasdaq:ADRO), today launched an innovative Immunotherapeutics and Vaccine Research Initiative (IVRI). IVRI is UC Berkeley’s first-ever immunotherapy-focused initiative and, in partnership with Aduro, will combine UC Berkeley’s extensive research capabilities with the company’s expertise in immunotherapy discovery and development to identify and advance new treatment options and preventive modalities for cancer, infectious disease and autoimmune disease. IVRI is designed to explore the unique synergy between cancer and infectious disease research and to accelerate breakthrough discoveries in both areas. IVRI researchers are working closely with collaborators and sponsors with the shared goal of discovering and advancing immunotherapeutics and vaccine strategies. “In the last several years, we have learned so much about the role of the immune system in treating disease, and we look forward to harnessing that information across both research and industry to develop innovative new treatment options to improve patient care,” said David Raulet, Faculty Director of the IVRI and a Professor of Immunology and Pathogenesis at University of California, Berkeley. “Through this initiative, we will leverage our powerful research networks to understand how we can better engage the immune system in treating cancer, infectious disease and autoimmune disease. By doing this, we hope to develop new methods for targeting and effectively controlling many different cancers, autoimmune and infectious diseases. Our goal is for these findings to pave the way for the development of innovative new treatment options.”

24

Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer

BERKELEY, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient has been dosed in SEASCAPE, the Phase 1/2 clinical study designed to evaluate the safety, tolerability and preliminary efficacy of CRS-207, Aduro’s lead listeria-based immunotherapy construct (LADD), in combination with epacadostat (INCB24360), Incyte Corporation’s (Nasdaq:INCY) selective IDO1 inhibitor, in patients with ovarian cancer. “By combining two immuno-oncology therapies which we believe have synergistic mechanisms of action, we andIncyte look forward to potentially advancing new treatment options for patients with ovarian cancer that could result in more effective therapy than either therapy alone,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Combination therapy is rapidly emerging as a new paradigm for immuno-oncology. With our three diverse technology platforms – LADD (listeria-based therapy), STING pathway activators and monoclonal antibodies – we intend to continue to identify new opportunities to improve patient care.” SEASCAPE (Study of Epacadostat and CRS-207 in Adults with Platinum Resistant Ovarian Cancer), co-funded byIncyte and Aduro, is designed to establish a recommended dose based on safety and tumor biomarkers for CRS-207 and epacadostat in Phase 1 followed by expansion into Phase 2 which will evaluate the combination at the recommended (or identified) dose level compared to CRS-207 alone. Aduro plans to enroll up to 40 patients in Phase 1 and up to 86 patients in Phase 2 with platinum-resistant ovarian, fallopian or peritoneal cancers. For more information about the study, visit www.clinicaltrials.gov and search identifier NCT02575807.

23

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy

DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial ofAGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC). The study is being conducted at the Cancer Research Network of Nebraska (CRNN) and is expected to enroll 20 patients. AGS-003 will be administered either concurrently with chemotherapy and with or without radiation or sequentially with chemotherapy and with or without radiation, according to the subject's assigned treatment arm. "The standard of treatment of NSCLC has been chemotherapy after surgery, but now we can offer this exciting new option of individualized immunotherapy," said Dr. Stephen Lemon, co-principal investigator and president of Oncology Associates, Omaha, Nebraska, a CRNN collaborating practice. "We are thrilled to participate in this exciting study and are hopeful that AGS-003will be safe and effective, and help our patients fight this terrible disease."

23

ENVISIA THERAPEUTICS SECURES $16.5 MILLION IN ADDITIONAL SERIES A FINANCING

RESEARCH TRIANGLE PARK, NC – March 23, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced a $16.5 million investment from existing investors to support the accelerated development of the Company’s pipeline of innovative extended-release ocular therapies for the three leading causes of preventable vision loss and blindness. “We are very pleased with the rapid progress we have made in the development of a portfolio of promising therapeutics and grateful for the continued support of our investors,” said Benjamin Yerxa, President. “This financing will be used to continue the clinical evaluation of our lead product, ENV515 for glaucoma, through phase 2 studies and to advance two other products in our pipeline through key data milestones.” Envisia is focused on the development of novel ocular therapeutics, with current programs in glaucoma, diabetic macular edema (DME) and age-related macular degeneration (AMD).

23

VoiceBox Announces Scientific Advisory Board

Mar 23, 2016 - Distinguished Researchers Bring Expertise and Strategic Guidance to Help Advance VoiceBox’s Technology Development VoiceBox Technologies, a global provider of contextual voice technologies and natural language understanding (NLU) for automotive, mobile and IoT products, today announced the formation of a Scientific Advisory Board. The diverse, world-class roster represents VoiceBox’s continued investment in its broader strategy to become a unifying interface for the Internet of Things. Board members include distinguished researchers in the fields of Artificial Intelligence (AI), multimodal human-computer interaction, biometrics, speech recognition, natural language understanding and dialog processing technologies. “Our vision of a common, intelligent interface – multi-device, cross-device and multi-user – integrates exciting new technologies to supplement our comprehensive, advantaged voice offerings,” said Mike Kennewick, VoiceBox’s CEO. “By integrating world-renowned talent regardless of location, we are able to build a team the expertise of which rivals the largest companies in our industry.”

16

ARCHITIZER A+ POPULAR CHOICE AWARDS AND PUBLIC VOTING

The IrisVR Mobile App has been selected as a Finalist in the Architizer A+ Awards for the Technology: Apps category. We're thrilled to be in the running. Help us win by voting here. Not to be outdone, the IrisVR Prospect Desktop App has been selected as a Special Mention for the Technology: Apps category. Out of thousands of submissions, it scored in the top 15% of entrants to achieve this special honor.

11

HD Biosciences Received Numerous "Vendor Appreciation and Special Contribution" Awards from Its Partners and Clients for the Impacts to Their Drug Discovery Portfolio Development

Shanghai, China – March 11, 2016 - HD Biosciences Co., Ltd. (HDB), a leading biology-focused preclinical Contract Research Organization (CRO), discloses today that, for the past three months, several project teams, business managers and a few dozens of scientists have received various awards from HDB’s partners and clients to recognize exceptional performance and valuable deliveries on collaboration. "Various awards and appreciations presented from our partners are strong demonstration of our high quality services and commitments of our staff to the jobs that they are associated with. These are also indications that the company business strategy to focus on value impacts of our services to clients' portfolio being paid off." Dr. Xuehai Tan, President & CEO of HDB commented in his remark. "We will continue to firmly stick to our core competences and invest on our teams to build a special global CRO, with which, partners and clients can develop their expectations." The awards from clients mainly cover the areas including plate-based pharmacology, target validation, anti-infectious disease, preclinical candidate (PCC) development, safety profiling, and project management, logistics supports etc.

09

InSilixa Inc. and DNA Software Inc. enter into agreement to develop state-of-the-art high-multiplex infectious disease panels for commercialization on InSilixa’s CMOS biochip platform

Sunnyvale, CA – March 9th, 2016. InSilixa Inc., the pioneer in the use of CMOS biochip technology for molecular diagnostics (MDx) and DNA Software Inc., a leader in DNA diagnostic design and analysis solutions, announces a joint agreement to develop Infectious disease assays specifically for InSilixa’s sample-to-answer CMOS biochip platform. InSilixa’s proprietary sample-to-answer CMOS biochip technology enables rapid detection, quantification, and genotyping of pathogens (viruses and bacteria) in clinical samples and the simultaneous identification of their drug resistance profiles using a highly-multiplexed targeted mutation detection technique. The first generation of InSilixa’s products will focus on infectious diseases MDx applications in near-patient and point-of-care (POC) settings, including the comprehensive analysis of seasonal respiratory infection outbreaks, rapid detection of MDR bacteria (“super bugs”) in urgent care settings and the detection, quantification and comprehensive drug resistance genotyping of the human immunodeficiency virus (HIV) in blood samples from patients with HIV/AIDS. The multiplexed PCR designs provided by DNAS Software will leverage their algorithms for signature sequence identification, ThermoBLASTTM for scanning oligonucleotides against collections of genomic sequences, and their PCR design software. “We are very excited to work with Dr. SantaLucia and his industry leading team at DNA Software to realize the full potential of our unique platform” said Dr. Arjang Hassibi, CEO of InSilixa Inc. “The agreement between InSIlixa and DNAS is a tremendous complement of technologies that will result in multiplexed detection of a wide variety of pathogens with outstanding sensitivity and specificity” said Dr. John SantaLucia, CEO of DNA Software, Inc.

08

Stealth BioTherapeutics Initiates Phase 2 Clinical Study of Elamipretide in Fuchs’ Corneal Endothelial Dystrophy

BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced the initiation of ReVEAL, a Phase 2 clinical study evaluating the topical eye drop formulation of elamipretide (formerly known as Ocuvia) for the treatment of patients with Fuchs’ corneal endothelial dystrophy (FCED). Top-line data from the study are expected in the third quarter of 2016. Fuchs’ is a late-onset, progressive disease of the cornea characterized by a reduction of endothelial cells, and can lead to edema or even blindness in more advanced cases. Elamipretide targets the inner mitochondrial membrane to help preserve mitochondrial energetics, loss of which is thought to lead to the onset of Fuchs’. “Many severe ocular diseases, including Fuchs’, are linked to dysfunctional mitochondria and are characterized by a state of increased oxidative stress and impaired energetic components of the eye. We are aiming to safely restore these energetics and to show a clinical benefit with elamipretide in visual acuity and other functional measures,” Stealth BioTherapeutics Chief Scientific Officer Mark Bamberger said. “This new trial furthers our ongoing commitment to uncovering the role mitochondrial dysfunction plays in ocular disorders, and how we might address unmet needs across several indications where impaired energetics are a final common pathway.”

01

HumanZyme Launches New XKine™ Recombinant Protein Line For Stem Cell Research and Regenerative Medicine Applications

March 1, 2016 -- HumanZyme Inc., a leading supplier of novel human proteins and growth factors to academic and biopharmaceutical customers enabling stem cell research and regenerative therapy applications, launched the new XKine™ product line broadening the company’s product offering. The new XKine™ human recombinant proteins are manufactured utilizing EColi or Chinese Hamster Ovary (CHO) host cell lines, expanding the number of research applications supported by HumanZyme. “The new XKine products are priced competitively selected carefully to support current pathway analysis, allowing our customers to purchase these products from HumanZyme, without the need to go to a 3rd party supplier as previously required, ” said Scott Coleridge, CEO at HumanZyme. The new XKine recombinant human protein line includes IL-11, IL-15, IL-34, IL35, IL5, IL8(CxXL8), LIF, Neurturin, PDGF-BB, Rantes(CCL5) sCD40 ligand, sTrail/apo2L, BDNF, CTGF, EGF and FGF-acidic etc. We will keep adding more recombinant proteins and cytokines to this growing product line.

February 2016

22

VoiceBox and Samsung announce partnership for S Voice technology

February 22, 2016 - Language technology startup VoiceBox announced a partnership with Samsung to use VoiceBox’s Natural Language Understanding (NLU) technology for Samsung’s S Voice services, including Samsung’s intelligent personal assistant. Currently, S Voice can assist Samsung mobile users with placing calls, sending texts, making appointments, updating social network websites, opening apps, and navigation. It also offers automatic activation features — for example, starting your car engine from outside the car — and can respond to questions. The new deal with Bellevue, Wash.-based VoiceBox is aimed at helping S Voice keep up with artificial intelligence competitors, like Apple’s Siri, Microsoft’s Cortana, and Amazon’s Alexa.

18

VoiceBox Technologies’ Solutions to be Leveraged Across Samsung’s Mobile Devices

BELLEVUE, USA – February 18, 2016 –VoiceBox Technologies Corporation today announced a strategic partnership with Samsung to use VoiceBox’s Natural Language Understanding (NLU) technology for Samsung’s voice services. The companies have been working closely together to build an intelligent assistant powered by VoiceBox’s NLU technology. “We are proud to have been selected to power the voice services on a range of existing and new Samsung mobile devices,” said Mike Kennewick, CEO of VoiceBox. “We look forward to collaborating on other opportunities with Samsung, particularly relative to our Smart Home and Internet of Things initiatives.” “Samsung understands that voice is a critical technology for its future. We are pleased to partner with VoiceBox and this collaboration will enable us to provide users with a powerful voice experience,” said Peter Koo, Senior Vice President Samsung Mobile.

18

Idibon AI processes world-scale text data … on a single computer!

Idibon News / Rob Munro/Thursday, February 18th, 2016 Idibon is announcing the launch of a new Machine Learning library, IdiML, for ultra-low latency text analytics at scale. Artificial Intelligence has become common in business, especially in big data processing. For most companies, it has simply been impossible to process the amount of data produced by large scale text processes like social media services, or to apply fast machine learning for real-time human interaction. We are aiming to solve this for everyone. IdiML is so fast, you can process the entire Twitter Firehose in real-time on the CPU of a single laptop, still leaving half the CPU capacity free! The breakthrough comes from intelligent in-memory processing that allows the information to be extracted without expensive database or file lookups. IdiML intelligently pre-compiles information from deep-learning, feature extraction, and client-defined semantic libraries, making the knowledge highly available through compression and in-memory data structures. At the point of processing, this allows a minimum number of passes to be made over the text, with our artificial intelligence extracting information continuously over the stream of data at breakneck speeds.

12

Apellis Completes $47 Million Series D Financing

LOUISVILLE, Ky., Feb. 12, 2016 /PRNewswire/ -- Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital. The proceeds of the financing will be used to further advance clinical trials in the Company's ongoing complement immunotherapy programs, including paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), an advanced form of dry type age-related macular degeneration (AMD), as well as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). "Our unique approach to broadly inhibit complement C3, the central protein in the complement cascade, is designed to significantly transform the treatments of patients with autoimmune and inflammatory diseases," commented Cedric Francois, M.D., Ph.D., founder and Chief Executive Officer of Apellis. "This financing allows us to advance our broad pipeline, resulting in up to three clinical programs by the end of 2016. We are excited to welcome three new investors to the Apellis team," he added. Robert Adelman, M.D., of venBio and Bihua Chen of Cormorant joined the Board of Directors.

09

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors

HOUSTON, Feb. 9, 2016 /PRNewswire/ -- DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced that its lead product, DNX-2401, has been designated by the European Commission as an orphan medicinal product for the treatment of glioma. Glioblastoma, the deadliest form of glioma, strikes approximately 25,000 people a year in the US and EU. Sponsors who obtain orphan designation benefit from a number of incentives, including protocol assistance, scientific advice specific for designated orphan medicines, and market exclusivity once the medicine is on the market. "We are pleased that the European Commission has recognized the potential benefits of our immunotherapy product for the treatment of brain tumors," said Frank Tufaro, Ph.D., CEO of DNAtrix, "We plan to continue our aggressive development program in the EU."

03

ENYO Pharma announces closing of a €22 million funding round

Lyon, 3 February 2016. ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, today announced that it has secured a €22 million Series A financing round. The investment is intended to help the company roll out its clinical hepatitis-B programme more quickly. The deal was led by Sofinnova Partners, alongside Morningside and Bpifrance via its fund InnoBio, and should enable ENYO Pharma to conduct Phase I trials in the first half of 2016, and phase II trials on chronic hepatitis B sufferers should follow by 2017.

01

Coming to Atlanta – Eye Exams at the Office!

BOSTON--(BUSINESS WIRE)--For today’s workforce, it’s hard to squeeze in important medical appointments, and in general, find that elusive work-life balance. According to the Center for Disease Control and Prevention, an estimated 61 million adults in the US are at risk for vision loss, yet only half had gone to the eye doctor in the previous 12 months. New this spring, Atlanta employers can help make getting an eye exam faster and easier for their employees. Why make thousands of people commute to the eye doctor when the eye doctor can simply come to them? That’s how Boston-based 2020 On-site Optometry is revolutionizing eye care. Having launched their first Mobile Vision Center in 2014, 2020 On-site has partnered with over 160 corporate clients and seen over 8,000 patients in the Boston area. “We are incredibly excited to be entering the Atlanta market,” said 2020 On-site CEO Howard Bornstein. “Traction at major, national employers based throughout the US with offices in Atlanta, Boston and elsewhere makes it apparent that we are solving a broad, latent need.”

01

Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen

BERKELEY, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the company received $22.4 million in clinical development milestone payments from Janssen Biotech, Inc., the company’s license partner for ADU-214, ADU-741 and other products using Aduro’s LADD technology platform for the treatment of specific cancers. Janssen is responsible for all clinical development for the product candidates within the license agreements. “Our relationship with Janssen has been exceptionally productive, with ADU-214 for the treatment of lung cancer and ADU-741 for the treatment of prostate cancer advancing in clinical studies,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We believe these therapeutics may offer important alternatives for patients suffering from these aggressive cancers.”

January 2016

29

Green Biologics Named in the 2015 Global Cleantech 100

Gahanna, Ohio and Abingdon, England (January 29, 2016) – Green Biologics Ltd., a U.K. based industrial biotechnology and renewable chemicals company, today announced it has once again been named to the prestigious 2015 Global Cleantech 100, produced by Cleantech Group, a leading global research and advisory firm. Green Biologics was recognized for its Clostridium fermentation platform, which converts a wide range of sustainable feedstocks into high performance green chemicals such as n-butanol and acetone for use by the growing consumer and industrial products industries. The Global Cleantech 100 is a comprehensive list of the private companies poised to make the most significant impact on the cleantech industry through innovative and promising technologies aimed at addressing tomorrow’s clean technology challenges. The list is collated by sifting through thousands of nominations and combining proprietary Cleantech Group research data, with weighted qualitative judgments, and specific inputs from a global 100-person Expert Panel. We are pleased to once again be recognized as a leading clean technology company through inclusion in the Cleantech 100, said Sean Sutcliffe, Chief Executive of Green Biologics, Ltd. ͞During this past year, we’ve made significant progress on our path to becoming an industry-leading renewable specialty chemicals company. We began 2015 by securing significant financing and are proud of the progress that has been made toward the construction on our 100 percent renewable, bio-based n-butanol and acetone plant in Little Falls, MN.

26

LEICA BIOSYSTEMS AND ADVANCED CELL DIAGNOSTICS PARTNER TO DEVELOP AND COMMERCIALIZE RNASCOPE-BASED DIAGNOSTIC AND COMPANION DIAGNOSTIC TESTS

NEWCASTLE UPON TYNE, UK & HAYWARD, CALIFORNIA, USA, January 26, 2016 – Leica Biosystems, a global leader in anatomical pathology solutions & workflow automation, and Advanced Cell Diagnostics, Inc. (ACD), a world leader in RNA biomarker analysis for precision medicine, today announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD's RNAscope in situ hybridization (ISH) assays on Leica Biosystems' BOND clinical advanced staining instruments. The agreement supports Leica Biosystems' development and commercialization of fully automated RNAscope-based companion diagnostic (CDx) tests in partnership with biopharmaceutical companies. The combination of ACD's RNAscope technology with Leica Biosystems' fully automated pathology solutions allows the companies and laboratories in clinical markets to integrate the power of new RNA-based biomarker tests into the existing pathology workflow. These tests will be co-branded and commercialized exclusively by Leica Biosystems for use in clinical labs around the world. The market-leading RNAscope LS probes and reagents running on the Research Use Only BOND RX instrument will also be upgraded as ready-to-use kits with streamlined software, to make the system more robust and easy to use. The RNAscope LS products will continue to be branded and commercialized exclusively by ACD. The availability of RNAscope technology on both research and clinical advanced staining platforms provides a seamless path for diagnostic test developers to translate their research to the clinic.

20

VoiceBox Technologies Agrees to Acquire Speech Product Unit, Telisma

BELLEVUE, WA, USA/ FRANCE— January 20, 2016 — VoiceBox Technologies Corporation, a global leader in intelligent, contextual voice solutions for connected things, has agreed to acquire the speech product unit Telisma from OnMobile S.A. The transaction is expected to close January 31, 2016. Founded as a spinoff of France Telecom in 2000, Telisma provides speech recognition technology to numerous leading companies and brings an additional 14 years of expertise in embedded and server Automatic Speech Recognition (ASR) to VoiceBox. The industry award winning interactive voice response (IVR) solution teliSpeech™ is deployed around the world and currently handles more than one billion IVR calls per year in many different languages. “We’ve been collaborating with Telisma on a robust embedded ASR solution for the automotive market for a couple years now,” said Mike Kennewick, CEO of VoiceBox. “This acquisition represents a natural extension of VoiceBox solutions to global IVR markets and further expands our ability to deliver full voice services to current and future customers.”

12

Envisia Therapeutics Announces First Patient Dosed in Second Cohort of Novel Phase 2 Program Evaluating ENV515 in Patients with Glaucoma

RESEARCH TRIANGLE PARK, NC – January 12, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced it has dosed its first patient in the second cohort of the phase 2 clinical program evaluating the Company’s lead product candidate, ENV515. ENV515 is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. “We are encouraged by our initial clinical experience with ENV515 in glaucoma patients and have rapidly moved into the second cohort of our phase 2 program for advanced testing, which will provide more data in early 2016 to guide next steps for a larger, multi-center, masked trial,” said Benjamin Yerxa, President of Envisia. “The progress of the ENV515 program further supports the potential of the proprietary PRINT® technology platform to accelerate drug development for front and back of the eye diseases.” “Envisia’s novel approach may dramatically change the way we treat glaucoma, especially since poor patient adherence with eye drops is associated with blindness and visual impairment from glaucoma,” said Steven L. Mansberger, MD, MPH, Vice-Chair, Director of Glaucoma Services at Devers Eye Institute and lead investigator for the ENV515 phase 2a trial. “This study may provide evidence that one-to-two injections per year of ENV515 in the doctor’s office could control the IOP in most glaucoma patients without the need for them to apply daily eye drops.”

07

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

Boston- January 7, 2016- Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of primary mitochondrial myopathy, characterized by muscle weakness in patients with genetic mitochondrial diseases. MTP-131 is currently being studied for the treatment of primary mitochondrial myopathy in its MMPOWER trial, with results expected midyear. Genetic mitochondrial diseases are a diverse group of rare inherited disorders characterized by systemic mitochondrial dysfunction that impairs patient health and well-being. MTP-131 is an investigational drug targeting the inner mitochondrial membrane to help preserve mitochondrial energetics and restore the healthy physiology which is often impaired in many rare and common diseases.

December 2015

29

New Mitochondrial Therapy Based on Bioenergetics Advancing in Range of Clinical Trials | Stealth BioTherapeutics' MTP-131 under study for skeletal muscle and cardio-renal ills linked to mitochondrial dysfunction

In the pipeline at Stealth BioTherapeutics is a new therapy, MTP-131, with the potential to treat individuals with mitochondrial disease and other diseases affected by mitochondrial dysfunction. The systemic version of MTP-131 (also known as Bendavia) is in clinical trials for skeletal muscle and cardio-renal diseases. The topical eye drop version (also known as Ocuvia) is on track to initiate clinical trials into Fuchs’ corneal endothelial dystrophy and Leber’s hereditary neuropathy in early 2016. “Our lead compound, MTP-131, is being tested in therapeutic areas where mitochondria have the highest impact: heart, skeletal muscle, and the eye,” said Dr. Mark Bamberger, chief scientific officer of Stealth BioTherapeutics. “In collaboration with mitochondrial experts, we are looking at the organs with the most mitochondria (e.g., the heart) or that produce the most energy (e.g., muscle tissue and the eye). Mitochondrial function is involved in many different diseases. The key is which disease areas to focus.”

21

Aduro Biotech Announces Initiation of Phase 1 Study of ADU-741 for the Treatment of Prostate Cancer

BERKELEY, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the first patient in the Phase 1 study of ADU-741 (also known as JNJ-64041809), a LADD immunotherapy product candidate for the treatment of prostate cancer, has been dosed. Janssen Biotech, Inc., is Aduro’s license partner for ADU-741. Janssen is conducting the study. “Janssen has deep expertise in the development of therapeutics for prostate cancer and we are extremely pleased with the rapid advancement of ADU-741 into clinical trials,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “ADU-741 represents a highly-specific, multifaceted approach to stimulate the immune system to fight cancer and we believe it may offer a new and unique treatment alternative to improve the outcome of men suffering from metastatic castration-resistant prostate cancer. We are particularly excited about ADU-741, which represents a significant advancement of our LADD technology and utilizes our proprietary methods to express multiple antigens that are relevant to prostate cancer. By engaging in productive agreements with partners like Janssen, Novartis and Incyte, we expand the reach of our novel immuno-oncology platform and offset the development costs of our internal therapies, all of which we pursue for the ultimate goal of bringing new treatments to patients in need.” The Phase 1 study will enroll approximately 40 patients with metastatic castration-resistant prostate cancer. The initial dose escalation portion of the trial, with two dose levels of ADU-741, will evaluate safety and immunogenicity. The trial will then expand to further characterize safety and preliminary immunological and clinical activity. Additional information may be found at clinicaltrials.gov, using identifier NCT02625857.

14

Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 and GVAX Pancreas for the Treatment of Pancreatic Cancer

BERKELEY, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 and GVAX for the treatment of pancreatic cancer. “We are extremely pleased to receive Orphan Drug Designation in the EU for CRS-207 and GVAX pancreas, which, taken together with our Breakthrough Designation granted by the U.S. Food and Drug Administration in the U.S., represent important regulatory milestones in our global strategy to develop new immunotherapies for this underserved population,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “As an integral step in our pursuit to bring this combination to patients with pancreatic cancer, we expect to report topline results from the ongoing Phase 2b ECLIPSE study evaluating this combination in the first half of 2016.”

10

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis

DURHAM, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immunooncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced its independent data monitoring committee (IDMC) has recommended the continuation of the company's pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee's second planned interim data analysis. "The ADAPT phase 3 trial to evaluate AGS-003 in front line mRCC, the largest global trial ever performed in newly diagnosed, unfavorable risk mRCC patients, continues to progress nicely," said Dr. Figlin, the Steven Spielberg Family chair in hematology oncology, professor of medicine and biomedical sciences at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the principal investigator for the ADAPT trial. "We anticipate that we are approaching the mid-point for the expected number of events and look forward to the next interim review of the trial data in approximately six months."

10

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer

BERKELEY, Calif., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the start of the Phase 1 study of ADU-214 (also known as JNJ-64041757), a LADD immuno-oncology therapy for the treatment of lung cancer, with the dosing of the first patient in the trial. Janssen Biotech, Inc., Aduro’s license partner for ADU-214, is conducting the multi-center study. “We are extremely pleased to see the first immuno-oncology therapy resulting from our license agreement with Janssen enter the clinic,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “With more than 200,000 new diagnoses this year and over 400,000 people living with lung cancer in the United Statesalone, new therapeutics are desperately needed. We believe ADU-214 may offer new hope to patients suffering from this aggressive disease.”

02

Green Biologics Starts Construction in Little Falls, MN

Gahanna, Ohio and Abingdon, England (December 2, 2015) – Green Biologics Ltd., a U.K. based industrial biotechnology and renewable chemicals company, is moving forward with the construction of its 100 percent renewable, bio-based n-butanol and acetone manufacturing facility in Little Falls, MN. The existing manufacturing site, formerly known as The Central MN Ethanol Cooperative (CMEC), was acquired by Green Biologics in December 2014 and re-named Central MN Renewables (CMR). Permitting was completed in late August and the construction began on September 1, 2015. Commercial production is scheduled to commence in 2016. The commencement of this construction project marks a significant milestone in our commitment to becoming a world class renewable specialty chemicals company, said Sean Sutcliffe, Chief Executive of Green Biologics, Ltd. In November, Green Biologics gained membership to the American Chemistry Council and started implementation of a comprehensive Responsible Care® initiative.

November 2015

23

Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma

BERKELEY, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 for the treatment of malignant pleural mesothelioma (MPM). “The receipt of Orphan Drug Designation in the European Union (EU) for CRS-207 for the treatment of MPM marks a significant regulatory milestone for Aduro, as we expand our operations in Europe and advance our therapies closer to the commercial marketplace,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We look forward to working with the EMA to expeditiously advance CRS-207 through development with the goal of bringing this potential therapy to patients throughout Europe suffering from mesothelioma.” To receive Orphan Drug Designation from the EMA, a therapy must be intended for the treatment of a life-threatening or chronically debilitating rare condition with a prevalence of less than five in 10,000 in the European Union. Orphan Drug Designation provides incentives designed to facilitate development, including protocol assistance and scientific advice and importantly, may provide up to ten years of market exclusivity in the EU following product approval.

09

Aduro Biotech Announces Five Poster Presentations at the Society of Immunotherapy of Cancer Annual Meeting

BERKELEY, Calif. – November 9, 2015 - Aduro Biotech, Inc. (Nasdaq: ADRO) today announced five posters highlighting ongoing clinical trials and pre-clinical programs investigating its novel immunotherapies in development for the treatment of cancer were presented at the Society for Immunotherapy of Cancer Annual Meeting held in National Harbor, Maryland last week. In a poster presented on Saturday, November 7, 2015 by Nitya Nair, Ph.D., scientist at Aduro, updated safety and efficacy data were shared from the Phase 2a clinical trial of Aduro’s novel immunotherapy CRS-207 in combination with GVAX Pancreas in patients with metastatic pancreatic cancer. Seven patients treated with this regimen survived for over three years, with one patient continuing to receive the combination regimen. In addition, the poster highlighted key biomarker findings in 38 patients from the 93-patient trial which demonstrated a statistically significant correlation between levels of certain immune cells in the peripheral blood and overall survival. Specifically, the data showed elevated subsets of CD8+ immune T cells at baseline and at seven weeks after treatment initiation resulted in better performance outcomes. Conversely, an increase in subsets of certain myeloid cells (CD14+) at the same time points was associated with worse outcomes.

03

MicuRx Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-I

HAYWARD, Calif. and SHANGHAI, Nov. 3, 2015 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced positive top-line results from its second Phase 2 clinical study of the drug candidate MRX-I. MRX-I is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as MRSA and VRE, while offering a safer and better tolerated oxazolidinone antibiotic therapy. "We are very pleased that results of MRX-I in the second Phase 2 clinical study performed in USA validate the therapeutic potential of this novel agent," said Dr. Zhengyu Yuan, president and CEO of MicuRx Pharmaceuticals, lnc. "For over 220 patients treated in US and China with MRX-I to-date, the response rates are consistently high. Importantly, MRX-I has not caused myelosuppression, the key limiting side effect of currently available oxazolidinone drugs."

October 2015

22

Chimerix Initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients

Durham, N.C. – October 22, 2015 – Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced initiation of dosing in SURPASS (ClinicalTrials.gov ID: NCT02439957), one of the two Phase 3 trials in the brincidofovir kidney transplant program. Both the SUSTAIN (ClinicalTrials.gov ID: NCT02439970) and SURPASS trials are evaluating brincidofovir for the prevention of cytomegalovirus (CMV) disease in kidney transplant recipients; both trials are now actively enrolling. Brincidofovir is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including herpesviruses and adenovirus, and demonstrated a clinically and statistically significant reduction in CMV infection in a Phase 2 trial in hematopoietic cell transplant (HCT) recipients. Based on that successful study, Chimerix designed and conducted the pivotal SUPPRESS trial for the prevention of clinically significant CMV infection in patients undergoing HCT which completed enrollment in June. Topline data from SUPPRESS are anticipated in early 2016.

21

Amgen Wins EU Green Light for First Virus-Based Cancer Drug

LONDON (Reuters) - A first-in-class drug from Amgen (formerly Morningside portfolio project Biovax) based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months. The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness. The European Medicines Agency (EMA) said its experts had recommended approval of Imlygic, also known as talimogene laherparepvec or "T-Vec", for treating melanoma, making it another option among several new drugs for the most deadly form of skin cancer.

20

CellCentric secures funding to take its prostate cancer programme to IND

Further investment from Morningside Venture Investments Ltd and Providence Investment Company Ltd will see the company take its small molecule drug discovery programme for the most aggressive form of prostate cancer (CRPC) through candidate finalisation and IND-enabling studies. CellCentric’s proprietary compounds target a histone acetyl transferase (HAT) that is key in androgen receptor regulation. For 10-20% of those with prostate cancer, long term survival prospects are poor. The aggressive form of the disease, castrate-resistant prostate cancer (CRPC), has a median survival time of 14 months. Two newer drugs on the market have some benefit, but cancer cells have multiple adaptive mechanisms that limit their effectiveness.

15

CellCentric successfully completes InnovateUK programme

CellCentric is developing small molecule inhibitors for the most aggressive form of prostate cancer (CRPC). In March 2013, the company secured support from InnovateUK, combined with venture capital investment, to develop novel small molecule modulators of the androgen receptor pathway. This programme has now completed, on time and on budget. Castrate resistant prostate cancer is a significant unmet clinical need. It effects up to 20% of prostate cancer suffers, and is rapidly lethal. The pharmaceutical market for drugs in this space is significant. Existing therapies, which have limited effectiveness, are project to be worth over $9.5bn by 2020. Through its deep foundation in epigenetics, CellCentric identified novel ways to address CRPC, by targeting the androgen receptor pathway – key to the progression of the disease. The company won a significant award from InnovateUK through its BioMedical Catalyst scheme, to translate the scientific concept and early research data, through to small molecule inhibitors that could be advanced as drugs and tested in the clinic.

06

GSK obtains rights to inhaled nanoparticles made using Liquidia's PRINT platform

GlaxoSmithKline ($GSK) now has rights to develop inhaled therapeutics using Liquidia's PRINT particle engineering technology. The development builds on a drug delivery alliance between the two companies that commenced in 2012. In addition to the upfront payment made in 2012, Research Triangle Park, NC's Liquidia receives an additional option fee from GSK, continued R&D funding, and the opportunity to earn regulatory and milestone payments down the road. Liquidia retains its ability to independently develop an inhaled therapy for a particular disease field, according to a release. "We are very pleased with the progress that has been made over the past three years in our collaboration with GSK. They are a great partner in our exploration of inhaled therapeutic options using our novel PRINT technology," said Liquidia CEO Neal Fowler in a statement. "GSK's decision to exercise this option initiates a new and exciting chapter in our relationship. We remain confident in the strength of this collaboration to navigate the path ahead to develop novel inhaled therapies."

06

Envisia Therapeutics' Lead Product Candidate, ENV515, Achieves Primary Efficacy Endpoint in Phase 2A Glaucoma Clinical Trial

RESEARCH TRIANGLE PARK, NC – OCTOBER 6, 2015 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company’s lead product candidate, ENV515 (travoprost XR). In this phase 2a trial, ENV515 achieved its primary efficacy endpoint by demonstrating a statistically significant and clinically meaningful reduction in intraocular pressure (IOP) with results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution). ENV515 is engineered as a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) travoprost formulation that could offer sustained reduction in IOP for more than six months after a single dose.

01

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

KENILWORTH, N.J. & HOUSTON, Oct.1, 2015 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD- 1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. DNX-2401 is a conditionally replicative oncolytic adenovirus designed to specifically target cells defective in the Retinoblastoma (Rb) pathway, which is present in many cancers. Several DNX-2401 clinical studies have demonstrated a favorable safety profile and strong tumor-killing potential in patients with recurrent glioblastoma. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. KEYTRUDA is currently approved in the United States for certain types of advanced metastatic melanoma.

September 2015

24

Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion

BERKELEY, Calif. and OSS, The Netherlands, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) and BioNovion Holding B.V. announced today that they have entered into a definitive agreement for Aduro to acquire BioNovion, a privately held monoclonal antibody discovery and development company based in The Netherlands. The acquisition will further strengthen and expand Aduro's immunotherapy capabilities to now encompass monoclonal antibodies, including preclinical assets that inhibit clinically validated immune checkpoint pathways. Such immune checkpoint inhibitors could potentially be used alone or in combination with Aduro's LADD and CDN platforms to increase immunotherapy potency and durability. In addition, BioNovion has a rich pipeline of novel preclinical monoclonal antibodies which inhibit or activate unique immune response pathways that have a role in controlling the progression of diverse malignancies.

August 2015

04

Genocea Biosciences, Inc. Announces Closing of $50 Million Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of 3,850,000 shares of its common stock, at the public offering price of $13.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 577,500 shares of common stock at the same price. The net proceeds to Genocea from this offering are expected to be approximately $47 million.

June 2015

29

Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

BERKELEY, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that an independent Data Monitoring Committee (DMC) recommended that the Phase 2b ECLIPSE trial of its novel LADD and GVAX immunotherapies continue as planned without modification based on the successful outcome of a pre-specified futility analysis. The DMC assessment included an evaluation of interim primary efficacy and safety data from over half of the anticipated patient population enrolled in the trial.

18

Advanced Cell Diagnostics Completes $22 Million Series C Equity Financing

Hayward, CA – June 18, 2015 – Advanced Cell Diagnostics, Inc. (ACD), a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, announced today that it has raised $22 million in Series C equity financing, led by growth equity investor Summit Partners with participation from Kenson Ventures and existing investors, Morningside Ventures and New Leaf Venture Partners.

16

Kezar Life Sciences Closes $23M Series A Financing

SOUTH SAN FRANCISCO, Calif., June 16, 2015 /PRNewswire/ -- Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders, announced the completion of a Series A financing totaling $23 million. The capital raised in the Series A will be used to advance Kezar's lead immunoproteasome inhibitor candidate into Phase 1a and 1b clinical trials, with the goal of demonstrating safety and efficacy in patients with autoimmune disease. Kezar also intends to advance drug discovery programs targeting protein secretion.

10

Chimerix Prices Public Offering of Common Stock

DURHAM, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $39.75 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $150 million. The offering is expected to close on or about June 16, 2015, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.

09

Luqa Pharmaceuticals Completes US$15M Series A Financing

Hong Kong, S.A.R., June 9, 2015 – Luqa Pharmaceuticals, a China specialty care company that markets innovative solutions in dermatology and other specialty areas, announces the completion of a US$15 million round of fund raising. The new financing was led by Morningside Ventures. Proceeds will be used to expand, develop and fund on-going operations and commercialization of Luqa’s product range.

May 2015

26

Stealth BioTherapeutics Announces Positive Results in Bendavia Heart Failure Study: The PREVIEW Trial

BOSTON – May 26, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced positive heart failure results from its PREVIEW study showing Bendavia improved cardiac function for patients. The results were presented at the European Society of Cardiology (ESC) Heart Failure Congress in Seville, Spain, during a symposium focused on mitochondria’s role in chronic heart failure (CHF).

22

BioScale Launches New ViBE® Software v3 For Use On ViBE Platform To Further Increase Productivity And Cost-Efficiency In Drug Development

Billerica, Mass. — May 22, 2015 — BioScale, Inc., a leading supplier of novel protein measurement technology to accelerate the development of diagnostic and clinical applications, and biological and pharmaceutical products, today announced the launch of a new ViBE software v3 allowing use of the platform in GLP and drug development labs. The new software, enabling faster plate read times of one hour, lower reagent consumption, FDA 21 CFR Part 11 tools and LIMS connectivity, was introduced at the recently concluded Protein Engineering Summit (PEGS) conference in Boston.

19

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer

Lowell, MA and Houston, TX – May 19, 2015. Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone’s MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix’s lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

April 2015

28

InCarda Therapeutics Completes Over $5 Million Private Financing

San Francisco, California, April 28, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the completion of a Series A financing. In this financing, InCarda raised over $5 million with potential tranches totaling an additional $1.5 million. The lead investor in the financing was Morningside. Other investors include a consortium of physicians and other health care and high tech professionals. Reenie McCarthy, representing Morningside, will join InCarda’s board of directors. Proceeds from the financing will be used to further the company’s lead cardiovascular program for an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF).

27

Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

BOSTON – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic neuropathies. Optic neuropathies include a diverse group of genetic diseases characterized by vision loss due to mitochondrial dysfunction. Affecting more than 1 in 10,000 individuals, optic neuropathies are common to more than 20 inherited mitochondrial diseases. Stealth’s ophthalmology program is led by Ocuvia, an investigational drug targeting mitochondrial dysfunction to treat common and rare eye diseases. Ocuvia is currently being studied in patients with diabetic macular edema and dry age-related macular degeneration.

20

Aduro Biotech Announces Close of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Concurrent Private Placement

BERKELEY, Calif.--(BUSINESS WIRE)-- Aduro Biotech, Inc. (Nasdaq: ADRO) today announced the closing of its initial public offering of 8,050,000 shares of common stock at a price to the public of $17.00 per share, which included 1,050,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. Aduro estimates the net proceeds from the public offering were approximately $124.3 million after deducting the underwriting discount and estimated offering expenses. Aduro also today announced the closing of its concurrent private placement of 1,470,588 shares of common stock at a price of $17.00 per share, for estimated net proceeds of approximately an additional $25.0 million.

14

Aduro Biotech Announces Pricing of Its Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Apr. 14, 2015-- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discount. Aduro’s common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “ADRO” on April 15, 2015. The offering is expected to close on April 20, 2015, subject to customary closing conditions. Aduro estimates net proceeds from the offering will be approximately $107.7 million (assuming no exercise of the underwriters’ option to purchase additional shares of common stock), after deducting the underwriting discount and estimated offering expenses payable by Aduro. Aduro’s net proceeds from a concurrent private placement at a price of $17.00 per share are expected to be $25.0 million.

01

New Platform Investment in Long Range Product Tankers

Morningside Private Investors (MPI) has purchased, along with management, two long range product tankers (LR1s) to transport refined product globally. Our Singapore-based ship management partners have experience managing different types of tankers ranging from smaller, specialized chemical tankers up to medium range product tankers. Our backing of this team allows them to enter a new market in the Panamax sized (75k DWT) shipping category hauling clean products such as diesel, gasoline, jet fuel and naptha.

March 2015

30

Aduro Biotech Establishes Collaboration with Novartis for Research and Development of Immuno-Oncology Products

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the establishment of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses. Aduro will receive $200M upfront, equity stake and future potential milestones collectively totaling up to $750M, plus profit sharing in the collaboration.

26

Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma

BERKELEY, Calif.--(BUSINESS WIRE)-- Aduro Biotech, Inc. today announced that the Office of Orphan Product Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CRS-207, a novel immuno-oncology product candidate, for the treatment of mesothelioma. This designation potentially allows Aduro seven years of limited marketing exclusivity in the United States if it is the first to obtain FDA marketing approval for mesothelioma, and qualifies the company for grant funding to offset the cost of clinical testing as well as tax credits for certain research and a waiver of the Biologics License Application user fee. The FDA previously granted orphan designation to CRS-207 and GVAX Pancreas for the treatment of pancreatic cancer.

17

Genocea Biosciences, Inc. Announces Closing of $51.7 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 818,181 shares of common stock, at the public offering price of $8.25 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Genocea to 6,272,726 shares and increased the total gross proceeds raised in this offering to $51.7 million, before deducting the underwriting discounts and commissions. The net proceeds to Genocea from this offering were approximately $48.4 million.

12

Genocea Biosciences, Inc. Announces Pricing of $45 Million Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the pricing of its public offering of 5,454,545 shares of its common stock at a public offering price of $8.25 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 818,181 shares of common stock at the same price. The offering is expected to close on or about March 17, 2015, subject to satisfaction of customary closing conditions.

February 2015

25

MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I

HAYWARD, Calif. and SHANGHAI, Feb. 25, 2015 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has received the approval from the U.S. Food and Drug Administration (FDA) to initiate Phase 2 clinical study in the United States for its lead drug candidate MRX-I. MRX-I, which demonstrated an enhanced safety profile over the market-leading comparator in Phase 1 studies, is an oral oxazolidinone antibiotic designed to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

17

Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases

BOSTON – Feb. 17, 2015 – Stealth BioTherapeutics (Stealth) today announced the initiation of a clinical study of Bendavia in patients with Mitochondrial Myopathy (MM). This study will investigate Bendavia for the treatment of myopathy (muscle weakness) in patients with genetic mitochondrial diseases. Genetic mitochondrial diseases are a diverse group of rare inherited disorders characterized by systemic mitochondrial dysfunction that impairs patient health and wellbeing. Bendavia is an investigational drug that targets the inner mitochondrial membrane to treat diseases both common and rare, including cardio-renal diseases and orphan mitochondrial diseases.

12

Chimerix Presents Update on Preliminary Data From AdVise Study of Brincidofovir for Adenovirus Infection at BMT Tandem Meetings

DURHAM, N.C., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) announced the presentation of preliminary data from the open-label, Phase 3 AdVise trial of brincidofovir for adenovirus infection showing a short-term mortality rate of less than 40 percent. The current analysis is based on the first 85 subjects enrolled and supports the trend seen in the first 48 subjects as presented at the meeting of the Infectious Diseases Society of America (IDSA), IDWeek. Historic mortality rates as high as 80 percent for disseminated adenovirus disease have been reported. These data will be presented today at 4:45 p.m. PT at the 2015 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplantation, taking place in San Diego, CA. Final trial results will be reported at a later date and will comprise clinical outcomes for trial subjects as compared to matched historical controls.

January 2015

29

Green Biologics to Convert Minnesota Ethanol Plant to N-Butanol and Acetone Facility

Green Biologics, a UK-based renewable chemicals company, has embarked on a major redevelopment process to turn a U.S. ethanol plant into an n-butanol and acetone facility to cater for the growing renewables-based paints and coatings industries. “Our strategy is to focus on supplying the renewable paints and coatings industry and other high value formulations markets and not fuels. We have now acquired an ethanol plant which will produce n-butanol and acetone from renewable sources,” Tim Staub, global vice president for Business Development said.

27

Envisia Therapeutics Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma

RESEARCH TRIANGLE PARK, NC – JANUARY 27, 2015 – Envisia Therapeutics today announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. ENV515 is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offers the potential to significantly address the poor compliance that exists among glaucoma patients today to limit disease progression and vision loss.

20

Aduro Biotech Reports Long-term Survival and Immune Biomarker Data From Phase 2 Clinical Trial of Its Immuno-oncology Regimen in Patients With Pancreatic Cancer

BERKELEY, Calif. -- Aduro Biotech, Inc. today announced that seven pancreatic cancer patients treated with its combination immuno-oncology regimen in a 93-patient Phase 2a clinical trial continue in survival follow-up, with two of those patients remaining on the company’s combination therapy for more than two years with no evidence of cumulative toxicity. Furthermore, the company reported data from ongoing immune monitoring analyses of the trial that show a statistically significant correlation in the breadth and quantity of patients’ antigen-specific CD8 T cell responses to treatment with overall survival. The analyses also identified a subset of cytokines that, when measured prior to treatment, correlated with longer overall survival. The data were presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium in San Francisco.

09

Stealth Biotherapeutics Expands Clinical Development for Mitochondrial Therapies

Boston, MA January 9, 2015—(BUSINESS WIRE)—Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today detailed its clinical development program in both common and rare diseases for its lead compounds, Bendavia and Ocuvia. Stealth is expanding its mitochondria-targeted therapies into several core areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. Stealth also announced that funding from its lead investor, Morningside, has surpassed $100M. The funding advances Stealth’s clinical development program for Bendavia and Ocuvia, and will help broaden its mitochondrial platform to include additional clinical candidates in 2015.

05

Aduro Biotech Closes $51.4 Million Series D Financing

BERKELEY, Calif. -- Aduro Biotech, Inc., a clinical-stage immuno-oncology company, today announced the closing of a $51.4 million Series D preferred stock financing. Eleven new investors participated in the round, including OrbiMed , Janus Capital Management LLC, funds managed by Franklin Advisers, Inc., Jennison Associates LLC (on behalf of certain clients), Foresite Capital Management LLC, certain private investment funds advised by Clough Capital Partners L.P., and other healthcare investors. The Morningside group and certain of the company’s existing investors also participated in the financing. Leerink Partners LLC acted as the exclusive placement agent for the financing.

December 2014

23

Green Biologics Closes Acquisition of Ethanol Plant in Minnesota

Gahanna, Ohio and Abingdon UK (December 23, 2014) - Green Biologics Inc. today announced the successful closing of its acquisition of the assets of Central MN Ethanol Cooperative LLC (CMEC). Green Biologics intends to repurpose the operation, which includes a 21 million gallon per year ethanol plant, to produce renewable nbutanol and acetone, utilising its proprietary advanced fermentation process (AFP™) technology platform. Green Biologics Inc. is a wholly owned U.S. subsidiary of Green Biologics Ltd., a UK industrial biotechnology and renewable chemicals company. The acquisition was make through Central MN Renewables LLC. (CMR), an affiliate of Green Biologics Inc. Current management and employees will continue with CMR. The plant is scheduled to begin production of renewable n-butanol and acetone in 2016, and will continue to produce ethanol until the repurposing is completed. The purchase was in accordance with an asset purchase agreement with CMEC previously announced on December 2, 2013. CMEC was represented in the transaction by Ocean Park Advisors, LLC.

03

Aduro Biotech Announces Preclinical Data Presented at American Association for Cancer Research Tumor Immunology and Immunotherapy Conference

ORLANDO, Fla.--(BUSINESS WIRE)-- Aduro Biotech, Inc., a leader in the development of therapies for immuno-oncology, today announced data demonstrating potent anti-tumor activity in preclinical models treated with ADU-S100, a proprietary molecule based on the company’s cyclic dinucleotide (CDN) platform technology. The data were presented by Thomas W. Dubensky, Jr., Ph.D., chief scientific officer of Aduro, at the American Association for Cancer Research Tumor Immunology and Immunotherapy Conference being held in Orlando this week.

02

Apellis Pharmaceuticals Raises $33M to Fund its Complement Immunotherapy Programs

LOUISVILLE, Ky., Dec. 2, 2014 /PRNewswire/ -- Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. The financing was led by Morningside Ventures and AJU IB Investment Co., Ltd. with Epidarex Ventures participating with follow-on funding. The proceeds will be used to fund three new complement immunotherapy programs entering clinical proof-of-concept stage.

November 2014

20

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

CRESTWOOD, Ky., Nov. 20, 2014 /PRNewswire/ -- Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration (dry AMD).

14

Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium

DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.

09

Mobile optometry service puts eye on convenience

By Cindy Atoji Keene GLOBE CORRESPONDENT NOVEMBER 09, 2014 The Boston startup Project 2020 aims to make it easier to get annual eye exams and basic preventive care, using the mobile clinic housed in its “eye truck” to bring services to the patients. It avoids all sorts of hassles, including having to drive after pupils have been dilated, said Alexa Baggio, director of operations. “We take a headache-inducing process and reduce it to 15 minutes, while increasing the quality of care,” said Baggio. Is this the next step in a broadly defined “mobile health”? We’re living in a convenience economy. Whether it’s mobile car detailers, manicures, or pet groomers, it’s easier to bring services directly to homes or businesses. Project 2020 is onsite optometry; the eye doctor comes to your office.